

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2019266525 B2**

(54) Title  
**Cyclopentane compounds**

(51) International Patent Classification(s)  
**C07D 401/08** (2006.01)                      **A61K 31/4545** (2006.01)  
**A61K 31/451** (2006.01)                      **A61P 13/12** (2006.01)  
**A61K 31/454** (2006.01)                      **C07D 211/56** (2006.01)

(21) Application No: **2019266525**                      (22) Date of Filing: **2019.05.09**

(87) WIPO No: **WO19/215268**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>PCT/CN2018/086503</b>	<b>2018.05.11</b>	<b>CN</b>

(43) Publication Date: **2019.11.14**

(44) Accepted Journal Date: **2024.06.13**

(71) Applicant(s)  
**Dizal (Jiangsu) Pharmaceutical Co., Ltd.**

(72) Inventor(s)  
**ZHANG, Xiaolin;PAN, Weitao;NIKITIDIS, Grigorios;LINDHAGEN, Jenny Susanna Marika**

(74) Agent / Attorney  
**Phillips Ormonde Fitzpatrick, PO Box 323, COLLINS STREET WEST, VIC, 8007, AU**

(56) Related Art  
**EP 2368876 A1**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
14 November 2019 (14.11.2019)



(10) International Publication Number  
**WO 2019/215268 A1**

(51) International Patent Classification:

C07D 401/08 (2006.01) A61K 31/451 (2006.01)  
C07D 211/56 (2006.01) A61K 31/454 (2006.01)  
A61P 13/12 (2006.01) A61K 31/4545 (2006.01)

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2019/061888

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

09 May 2019 (09.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/086503

11 May 2018 (11.05.2018) CN

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii))

(71) Applicant (for all designated States except ST): **AS-  
TRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventor; and

(71) Applicant (for ST only): **ZHANG, Xiaolin** [US/CN]; 1  
Francis Crick Avenue Cambridge Biomedical Campus,  
Cambridge Cambridgeshire CB2 0AA (GB).

(72) Inventors: **PAN, Weitao**; 1 Francis Crick Avenue Cam-  
bridge Biomedical Campus, Cambridge Cambridgeshire  
CB2 0AA (GB). **NIKITIDIS, Grigorios**; SE-151 85  
Södertälje (SE). **LINDHAGEN, Jenny, Susanna, Marika**;  
SE-151 85 Södertälje (SE).

(74) Agent: **LEESE, Mathew, Paul**; Milstein Building, Granta  
Park, Cambridge Cambridgeshire CB21 6GH (GB).

Published:


— with international search report (Art. 21(3))

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

(54) Title: CYCLOPENTANE COMPOUNDS

(57) Abstract: The present invention relates to cyclopentane com-  
pounds of Formula (I), physical forms thereof, processes for their pro-  
duction and their use in medicine.



(I)



WO 2019/215268 A1

5

Cyclopentane compounds

The present disclosure relates to substituted cyclopentane compounds and pharmaceutically acceptable salts thereof that inhibit the canonical Transient receptor potential channels TRPC6 and TRPC3. The present disclosure also relates to the use of these compounds, and pharmaceutically acceptable salts thereof, in medicine, for example in the treatment of diseases in which inhibition of TRPC6 or TRPC3 function is of therapeutic significance. The present disclosure also relates to methods of treatment and methods of manufacture of medicaments using compounds according to the disclosure.

Transient receptor potential channels (TRP channels) are a group of ion channels located mostly on the plasma membrane of certain mammalian cells. TRP channels commonly modulate ion entry driving forces, and the Ca<sup>2+</sup> and Mg<sup>2+</sup> transport machinery, in the plasma membrane. The seven canonical Transient receptor potential channels (TRPC channels) are potential cation channels that are activated by phospholipase C (PLC)-coupled receptors and can be subdivided into four subgroups: group 1 (TRPC1), group 2 (TRPC2), group 3 (TRPC3, TRPC6 and TRPC7) and group 4 (TRPC4 and TRPC5). Of these, the group 3 TRPCs, i.e. TRPC3, TRPC6, and TRPC7, interact physically and, upon coexpression, coassemble to form functional tetrameric channels. The sequence homology between TRPCs 3, 6 and 7 is nearly 75%.

TRPC6, a member of the canonical transient receptor potential (TRPC) subfamily, is a non-selective Ca<sup>2+</sup> channel expressed on podocytes that has an important role in the maintenance of glomerular barrier function. Activation of TRPC6 results in Ca<sup>2+</sup> influx and regulates podocyte morphology and motility. Upregulation of the TRPC6 signaling has been observed to cause damage of podocytes, resulting in severe proteinuria.

Focal segmental glomerulosclerosis (FSGS) is the most common cause of steroid-resistant nephrotic syndrome in both children and adults. The prognosis of untreated patients with FSGS is poor, with more than 60% of untreated patients progressing to end stage renal disease (ESRD), also often referred to as kidney failure, that is, in turn, the last stage of chronic kidney disease. Typically, the time from FSGS diagnosis to ESRD is around 10 years. Progression to ESRD can however be much more rapid, for example within 6 months. Literature reports suggest that as many as 20% of ESRD patients initially present with FSGS.

TRPC6 gain of function mutations are identified in the familial or sporadic type of FSGS with the phenotype of proteinuria and resistance to steroid treatment, the standard of care for FSGS. Development of resistance to steroid treatment can in turn eventually lead to chronic kidney disease (CKD). A significant number of patients with FSGS present with a mutation of Transient receptor


5 potential canonical 6 (TRPC6) that causes a gain of function (Winn et al, Science. 2005, 308 (5729):1801-4). Presence of TRPC6 gain-of-function mutations in FSGS are therefore of prognostic significance. Accordingly, inhibition of TRPC6 potentially offers a new opportunity for therapeutic intervention for the treatment of FSGS, especially for those patients with a TRPC6 gain of function mutation.

.0 TRPC channel function has also been associated with a number of other disorders, with TRPC3 upregulation having been observed in muscular dystrophy and associated with myofibre degeneration (Millay et al PNAS, 2009, 106(45): 19023–19028). Other conditions that are associated with TRPC3 include cardiac hypertrophy (Kiyonaka et al, PNAS 2009 106(13) 5400-5405). In addition to FSGS, TRPC6 has been associated with a range of conditions such as myocardial infarction (Varga-Szabo et al., J. Thromb. and Haemost. 2009, 7, 1057-1066) wherein loss of TRPC6 function has been linked to a slowing of the progression of cardiac dysfunction and cardiac remodelling in the post myocardial infarction heart in *in vivo* models (Gross et al, Circulation Research 2016, 119: A296); pulmonary hypertension (Yu et al, Circulation 2009, 119, 2313-22); skeletal muscle dysfunction (Millay et al, *ibid*); and cancer cell proliferation (Ding et al, J Natl Cancer Inst (2010) 102 (14): 1052-1068). TRPC6 and  
 !0 TRPC3 inhibitors therefore potentially have broad therapeutic application.

To the best of our knowledge, to date there have been no inhibitors of TRPC6 or TRPC3, nor dual inhibitors of TRPC6 and TRPC3 that have been approved for clinical use. Hence there is a need for new inhibitors of TRPC6 and/or TRPC3 with a pharmacological and pharmaceutical profile suitable for clinical use. The present specification is to provide new compounds that inhibit TRPC6 and TRPC3 that  
 !5 are suited for use as therapeutic agents.

We have now discovered, surprisingly, that the cyclopentane derivatives described herein are capable of inhibiting TRPC6 and TRPC3 and may therefore be useful for the treatment of conditions in which TRPC6 and TRPC3 function has pharmacological significance.

In one aspect, there is provided a compound of Formula I,



5

## Formula I

wherein:

- X is a) O, and R<sup>1</sup> is a 6-membered aromatic or heteroaromatic ring selected from phenyl, pyridyl, pyrimidyl, pyrazinyl or pyridazyl that is optionally substituted with one or two substituents Y that are independently selected from F, Cl, Br, CN, OH, OC<sub>1-3</sub>alkyl, OCF<sub>3</sub>, C<sub>1-3</sub>alkyl, C(O)NH<sub>2</sub>, CF<sub>3</sub> or cyclopropyl;
- 10 or b) NR<sup>2</sup>, and wherein N, R<sup>1</sup> and R<sup>2</sup> together form a 5-membered aromatic heterocycle that is optionally substituted with one or two substituents Y that are independently selected from F, Cl, CN, or Me;
- R<sup>3</sup> is independently selected from F, Cl, CN, methyl, methoxy, hydroxy and ethynyl;
- R<sup>4</sup> is independently selected from F or Cl attached to C2, C4 or C5 of the piperidine ring; and
- 15 the integers a and b are independently selected from 0, 1 or 2;
- or a pharmaceutically acceptable salt thereof.

In a further aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable diluent, excipient or inert carrier.

- 20 In a further aspect, there is provided a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in treatment or prophylaxis of diseases and conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial. In embodiments, the specification provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the treatment of kidney disease. In embodiments, the kidney disease is focal segmental glomerulosclerosis (FSGS). In embodiments, the kidney disease
- 25 is focal segmental glomerulosclerosis (FSGS) with a TRPC6 gain of function mutation.

- In a further aspect, there is provided a method of treating diseases or conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial, comprising administering to a patient in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. In one embodiment, said disease or condition is kidney disease. In embodiments, the kidney disease is focal
- 30 segmental glomerulosclerosis (FSGS). In embodiments, the kidney disease is focal segmental glomerulosclerosis (FSGS) with a TRPC6 gain of function mutation.

- In a further aspect, there is provided the compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicine for the treatment of diseases or conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial. In one embodiment, said disease or condition is kidney
- 35 disease. In another embodiment, the kidney disease is focal segmental glomerulosclerosis (FSGS). In

5 embodiments, the kidney disease is focal segmental glomerulosclerosis (FSGS) with a TRPC6 gain of function mutation.

In a further aspect, is provided a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in medicine.

10 In further aspect, there is provided a process for the preparation of a compound of Formula I, and the intermediates used in the preparation thereof.


In a further aspect, the compound of Formula I is (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine. In embodiments, (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine is provided in a crystalline form, for example a single crystalline polymorph Form A as further described herein.

15 These and other aspects of the present application are described in greater detail herein below.

The compounds of Formula I have a number of asymmetric carbons, for example, when  $b = 1$  there are two asymmetric carbons on the piperidine ring, at C3 and C5, and three on the cyclopentane ring, at C1, C2 and C4. The present description encompasses all of the possible enantiomers and diastereoisomers of the compounds of Formula I.


20 For the purpose of this specification, the term "5-membered aromatic heterocycle" means a 5-membered aromatic ring comprising 1 to 4 nitrogen atoms. Examples of suitable 5-membered aromatic heterocycles include pyrrolyl, imidazolyl, pyrazolyl, triazolyl and tetrazolyl.

For the avoidance of doubt, when the positions C2 to C5 on the piperidine ring are referred to in this specification, it is in reference to the positions on the piperidine ring as labeled below;



25

In embodiments the compound of Formula is a compound of Formula Ia wherein the asymmetric carbon at C3 of the piperidine group is in the (R)-configuration.




5


Formula Ia

For example, the compound of Formula Ia may be a compound of Formula Ia<sub>i</sub> wherein the asymmetric carbons at C3 and C5 of the piperidine group are in the (R)-configuration i.e. the compound of Formula Ia is (3R,5R)-5-fluoro-1-[4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine as shown below.

10

Formula Ia<sub>i</sub>


Embodiments of the compounds of Formula I and Ia, include compounds of Formula Ib wherein the group XR<sup>1</sup> and piperidine groups are *trans* to each other.



15

Diastereoisomers of Formula Ib


- 5 Thus, in the case wherein the stereochemistry of the groups on the piperidine ring are not specified the compound may be a compound of Formula **Ibi**, *i.e.* 5-fluoro-1-[(1R,2R)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine or 5-fluoro-1-[(1S,2S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine as shown below.



10

Diastereoisomers of Formula **Ibi**


Embodiments of the compounds of Formula **I**, **Ia** and **Ib**, include compounds of Formula **Ic** wherein the piperidine and phenyl groups are *cis* to each other.



15

Diastereoisomers of Formula **Ic**


Thus, in the case where in the stereochemistry of the groups on the piperidine ring are not specified the compound of Formula **Ic** may be a compound of Formula **Ici** *i.e.* 5-fluoro-1-[(1R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine or 5-fluoro-1-[(1S,4R)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine as shown below.



5

Diastereoisomers of Formula Ici

Embodiments of the compounds of Formula I, **Ia**, **Ib**, and **Ic** include compounds of Formula **Id** wherein the piperidine and phenyl groups are *cis* to each other, and the piperidine and  $\text{XR}^1$  groups are *trans* to each other.




10

Diastereoisomers of Formula Id


Thus, in the case where in the stereochemistry of the groups on the piperidine ring are not specified the compound of Formula **Id** may be a compound of Formula **Idi**, i.e. 5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine or 5-fluoro-1-[(1S,2S,4R)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine.

15




Diastereoisomers of Formula Idi

- 5 In embodiments of Formula **Id** wherein the piperidine group is a 5-fluoro-(3R,5R)-piperidine-3-amine group, the compound of Formula **Id** may be (3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine or (3R,5R)-5-fluoro-1-[(1S,2S,4R)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine, as shown below.



- 10 In one embodiment, the compound of Formula **I** is (3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine.



- In embodiments, the compound of Formula **I**, **Ia**, **Ib**, **Ic** or **Id** is a compound of Formula **Ie** wherein the group X is O, and R<sup>1</sup> is a 6-membered aromatic or heteroaromatic ring selected from phenyl, pyridyl, pyrimidyl, pyrazinyl or pyridazyl that is optionally substituted with one or two substituents Y independently selected from F, Cl, Br, CN, OH, OC<sub>1-3</sub>alkyl, OCF<sub>3</sub>, C<sub>1-3</sub>alkyl, C(O)NH<sub>2</sub>, CF<sub>3</sub> or cyclopropyl.

In embodiments, the compound of Formula **Ie** is a compound of Formula **If** wherein at least one substituent on the 6-membered aromatic or heteroaromatic ring R<sup>1</sup> is selected from Me, Cl, F and CN.

- In embodiments, the compound of Formula **I**, **Ia**, **Ib**, **Ic** or **Id** is a compound of Formula **Ig** wherein the group XR<sup>1</sup> is NR<sup>2</sup>, and wherein N, R<sup>1</sup> and R<sup>2</sup> together form a 5-membered aromatic heterocycle that is optionally substituted with one or two substituents Y independently selected from F, Cl, CN, or Me

In embodiments, the compound of Formula **Ig** is a compound of Formula **Ih** wherein at least one substituent on the 5-membered aromatic heterocycle is selected from Me, Cl, F and CN.

5 In embodiments, the compound of Formula **Ig** is a compound of Formula **Ii** wherein the 5-membered aromatic heterocycle is unsubstituted.

In embodiments, the compound of Formula **I**, **Ia**, **Ib**, **Ic**, **Id**, **Ie**, **If**, **Ig**, **Ih** or **Ii** is a compound of Formula **Ij** wherein at least one substituent R<sup>3</sup> is para-to the bond to the cyclopentane ring.

10 In embodiments, the compound of Formula **Ij** is a compound of Formula **Ik** wherein the substituent R<sup>3</sup> is F and a = 1.

In embodiments, the compound of Formula **I**, **Ia**, **Ib**, **Ic**, **Id**, **Ie**, **If**, **Ig**, **Ih**, **Ii**, **Ij** or **Ik** is a compound of Formula **Il** wherein at least one group R<sup>4</sup> is F.

In embodiments, the compound of Formula **Il** is a compound of Formula **Im** wherein b = 1.

15 In embodiments, the compound of Formula **I**, **Ia**, **Ib**, **Ic**, **Id**, **Ie**, **If**, **Ig**, **Ih**, **Ii**, **Ij**, **Ik**, **Il** or **Im** is a compound of Formula **In**, wherein R<sup>4</sup> is independently selected from F or Cl attached to C4 or C5 of the piperidine ring.

In embodiments, the compound of Formula **I**, **Ia**, **Ib**, **Ic**, **Id**, **Ie**, **If**, **Ig**, **Ih**, **Ii**, **Ij**, **Ik**, **Il** or **Im** is a compound of Formula **Io**, wherein R<sup>4</sup> is F attached to C4 or C5 of the piperidine ring.

In embodiments, the compound of Formula **I**, **Ia**, **Ib**, **Ic** or **Id** is selected from:

- 20 1-[4-(4-fluorophenyl)-2-(triazol-2-yl)cyclopentyl]piperidin-3-amine;  
 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile;  
 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-3-carbonitrile;  
 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrrole-3-carbonitrile;  
 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]triazole-4-carbonitrile;  
 25 1-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile;  
 1-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile;  
 1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine;  
 5-fluoro-1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine;  
 5-fluoro-1-[4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine;  
 30 5-fluoro-1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine;  
 1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine;  
 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]-1,2,4-triazole-3-carbonitrile;  
 4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-hydroxy-phenyl)cyclopentoxyl]benzonitrile;  
 4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-methoxy-phenyl)cyclopentoxyl]benzonitrile;  
 35 4-[2-(3-amino-1-piperidyl)-4-(3-fluorophenyl)cyclopentoxyl]-3-chloro-benzonitrile;  
 4-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]benzonitrile;

- 5 4-[2-(5-amino-3,3-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]benzotrile  
 4-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]-2-fluoro-benzotrile;  
 2-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxyl]benzotrile;  
 4-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxyl]-3-chloro-benzotrile;  
 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]-5-methyl-pyridazine-3-  
 10 carbonitrile;  
 1-[2-(4-chloropyridazin-3-yl)oxy-4-(4-fluorophenyl)cyclopentyl]piperidin-3-amine;  
 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]pyridazine-3-carbonitrile;  
 1-[4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yl)oxy-cyclopentyl]piperidin-3-amine;  
 6-(2-((R)-3-aminopiperidin-1-yl)-4-(4-fluorophenyl)cyclopentyl)nicotinonitrile;  
 15 6-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]pyridine-3-carbonitrile;  
 1-[4-(4-fluorophenyl)-2-pyridazin-3-yloxy-cyclopentyl]piperidin-3-amine;  
 5-fluoro-1-[4-(4-fluorophenyl)-2-pyrimidin-4-yloxy-cyclopentyl]piperidin-3-amine;  
 2-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]pyrimidine-5-carbonitrile;  
 5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]pyrazine-2-carbonitrile; and  
 20 5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]pyrimidine-2-carbonitrile;  
 or a pharmaceutically acceptable salt thereof.

In one embodiment, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable diluent, excipient or inert carrier. In one embodiment, the  
 25 pharmaceutical composition comprises a compound of Formula I in the free base form.


In one embodiment, there is provided a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in treatment or prophylaxis of diseases and conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial. In one embodiment, the use of is for the treatment of kidney disease. In one embodiment, the kidney disease is focal segmental glomerulosclerosis (FSGS). In one  
 30 embodiment, the kidney disease is focal segmental glomerulosclerosis (FSGS) with a TRPC6 gain of function mutation as described in Winn et al, Science. 2005, 308 (5729):1801-4.

In one embodiment, there is provided a compound of Formula I or a pharmaceutically acceptable salt thereof for use in the preparation of a medicine for the treatment of diseases or conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial. In one embodiment, said disease or condition is kidney  
 35 disease. In one embodiment, the kidney disease is focal segmental glomerulosclerosis (FSGS), for example FSGS with a TRPC6 gain of function mutation.

- 5 In one embodiment, there is provided a method of treating a disease or condition in which inhibition of TRPC6 and/or TRPC3 is beneficial, comprising administering to a patient in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. In one embodiment, said disease or condition is kidney disease. In one embodiment, the kidney disease is focal segmental glomerulosclerosis (FSGS), for example FSGS with a gain of function mutation.
- 10 In one embodiment, is provided a compound of Formula I or a pharmaceutically acceptable salt thereof, for use as medicament.

In one embodiment, there is provided a process for the preparation of compounds of Formula I, and the intermediates used in the preparation thereof.

In one embodiment the process for the preparation of a compound of Formula I involves the step



wherein P is a suitable nitrogen protecting group. P may be a carbamate protecting group, for example a *tert*-butoxycarbonyl or Boc group. The aminopiperidine group may be provided in single enantiomeric or diastereomeric form. The aminopiperidine group may be provided with an e.e. of >95%, a d.e. of >95% or an e.e. of >95% and a d.e. of >95%.

- 20 It has been found that (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, also referred to herein as Compound **10**, may exist as a crystalline form, "Compound **10** Form A", or simply "Form A". One crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, i.e. Compound **10** Form A, provides an X-ray powder diffraction pattern substantially as shown in Figure 1.
- 25 One aspect provides a crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine.

Another aspect provides (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A, which exhibits the characteristic X-ray powder diffraction peaks (expressed in degrees  $2\theta$ ) as shown in Table 1 below, using  $\text{CuK}\alpha$  radiation.

5 (3R,5R)-5-Fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A is characterised in providing at least one of the following  $2\theta$  values measured using  $\text{CuK}\alpha$  radiation:  $17.1^\circ$  and  $20.2^\circ$ . (3R,5R)-5-Fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A is characterised in providing an X-ray powder diffraction pattern, substantially as shown in Figure A. The thirteen most prominent peaks are shown  
10 in Table 1:

**Table 1** The thirteen most prominent X-ray powder diffraction peaks for Compound 10, Form A

Angle 2-Theta ( $2\theta$ )	Intensity %	Relative Intensity
12.3	13.7%	s
13.4	12.8%	s
13.6	28.0%	vs
17.1	77.2%	vs
18.9	16.7%	s
20.2	100%	vs
20.9	12.8%	s
21.3	8.2%	m
21.8	20.1%	s
22.2	58.3%	vs
24.5	20.0%	s
25.3	13.1%	s
27.0	18.5%	s

w = weak m = medium s = strong vs = very strong (see also Table 3 below)

According to an embodiment of the present specification there is provided a crystalline form of  
15 (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A, which has an X-ray powder diffraction pattern with at least one specific peak at about  $2\text{-theta} = 17.1^\circ$ .

5 According to an embodiment of the present specification there is provided a crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A, which has an X-ray powder diffraction pattern with at least one specific peak at about 2-theta = 20.2°.

10 According to an embodiment of the present specification there is provided a crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A, which has an X-ray powder diffraction pattern with at least two specific peaks at about 2-theta = 17.1° and 20.2°.

15 According to an embodiment of the present specification there is provided a crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A, which has an X-ray powder diffraction pattern with specific peaks at about 2-theta = 12.3, 13.4, 13.6, 17.1, 18.9, 20.2, 20.9, 21.3, 21.8, 22.2, 24.5, 25.3 and 27.0°.

20 According to an embodiment of the present specification there is provided crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A, which has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 1.

According to an embodiment of the present specification there is provided a crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A, wherein said form has an X-ray powder diffraction pattern with at least one specific peak at 2-theta = 17.1° plus or minus 0.5° 2-theta.

25 According to an embodiment of the present specification there is provided a crystalline form, Form A, wherein said form has an X-ray powder diffraction pattern with at least one specific peak at 2-theta = 20.2° plus or minus 0.5° 2-theta.

30 According to an embodiment of the present specification there is provided a crystalline form, Form A, wherein said form has an X-ray powder diffraction pattern with at least two specific peaks at 2-theta = 17.1° and 20.2° wherein said values may be plus or minus 0.5° 2-theta.

According to an embodiment of the present specification there is provided a crystalline form, Form A, wherein said form has an X-ray powder diffraction pattern with specific peaks at 2-theta = 12.3, 13.4, 13.6, 17.1, 18.9, 20.2, 20.9, 21.3, 21.8, 22.2, 24.5, 25.3 and 27.0° wherein said values may be plus or minus 0.5° 2-theta.

5 When it is stated that embodiments of the present specification relate to a crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine the degree of crystallinity is conveniently greater than about 60%, more conveniently greater than about 80%, preferably greater than about 90% and more preferably greater than about 95%. Most preferably the degree of crystallinity is greater than about 98%.

10 The crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, Form A provides X-ray powder diffraction patterns substantially the same as the X-ray powder diffraction patterns shown in Figure 1 and has substantially the thirteen most prominent peaks (angle 2-theta values) shown in Table 1. It will be understood that the 2-theta values of the X-ray powder diffraction pattern may vary slightly from one machine to another or from  
15 one sample to another, and so the values quoted are not to be construed as absolute.

In this specification, unless otherwise stated, the term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication,  
20 commensurate with a reasonable benefit/risk ratio.

In this specification, unless otherwise stated, the phrase "effective amount" means an amount of a compound or composition which is sufficient enough to significantly and positively modify the symptoms and/or conditions to be treated (e.g., provide a positive clinical response). The effective amount of an active ingredient for use in a pharmaceutical composition will vary with the particular  
25 condition being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the particular active ingredient(s) being employed, the particular pharmaceutically-acceptable excipient(s)/carrier(s) utilized, and like factors within the knowledge and expertise of the attending physician.

The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating,  
30 inhibiting the progress of, delaying the progression of, delaying the onset of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above. The term "treating" also includes adjuvant and neo-adjuvant treatment of a subject. For the avoidance of doubt, reference herein to "treatment"  
35 includes reference to curative, palliative and prophylactic treatment, and to the administration of a medicament for use in such treatment.

5 The compounds of Formula I may form stable pharmaceutically acceptable acid or base salts, and in such cases administration of a compound as a salt may be appropriate. Examples of acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, 10 hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, meglumine, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), trifluoroacetate, and undecanoate. Non-toxic physiologically-acceptable salts are preferred, although other salts may be 15 useful, such as in isolating or purifying the product.

The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.

20 The compounds of Formula I have more than one chiral center, and it is to be understood that the application encompasses all individual stereoisomers, enantiomers and diastereoisomers and mixtures thereof. Thus, it is to be understood that, insofar as the compounds of Formula I can exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the application includes in its definition any such optically active or racemic form which possesses the 25 above-mentioned activity. The present application encompasses all such stereoisomers having activity as herein defined.

The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Racemates may be separated into individual enantiomers using known procedures 30 (see, for example, *Advanced Organic Chemistry: 3rd Edition*: author J. March, p104-107). A suitable procedure involves formation of diastereomeric derivatives by reaction of the racemic material with a chiral auxiliary, followed by separation, for example by chromatography, of the diastereomers and then cleavage of the auxiliary species. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

35 Thus, throughout the specification, where reference is made to the compound of Formula I it is to be understood that the term compound includes diastereoisomers, mixtures of diastereoisomers, and enantiomers that are TRPC6 and TRCP3 inhibitors.

5 Stereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The enantiomers may be isolated by separation of a racemate for example by fractional crystallisation, resolution or HPLC or SFC. The diastereoisomers may be isolated by separation by virtue of the different physical properties of the diastereoisomers, for example, by fractional crystallisation, HPLC or flash chromatography. Alternatively particular stereoisomers may be made by  
10 chiral synthesis from chiral starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, with a chiral reagent.

When a specific stereoisomer is provided (whether provided by separation, by chiral synthesis, or by other methods) it is favorably provided substantially isolated from other stereoisomers of the same compound. In one aspect, a mixture containing a particular stereoisomer of a compound of Formula  
15 I may contain less than 30%, particularly less than 20%, and more particularly less than 10% by weight of other stereoisomers of the same compound. In another aspect, a mixture containing a particular stereoisomer of the compound of Formula I may contain less than 6%, particularly less than 3%, and more particularly less than 2% by weight of other stereoisomers of the compound. In another aspect, a mixture containing a particular stereoisomer of the compound of Formula I may contain less than  
20 1%, particularly less than 0.5%, and more particularly less than 0.3%, and still more particularly less than 0.1% by weight of other stereoisomers of the compound.

It is also to be understood that certain compounds of Formula I, and pharmaceutically salts thereof, can exist in solvated as well as unsolvated forms such as, for example, hydrated and anhydrous forms. It is to be understood that the compounds herein encompass all such solvated forms. For the sake of  
25 clarity, this includes both solvated (e.g., hydrated) forms of the free form of the compound, as well as solvated (e.g., hydrated) forms of the salt of the compound.

Formula I as described herein is intended to encompass all isotopes of its constituent atoms. For example, H (or hydrogen) includes any isotopic form of hydrogen including  $^1\text{H}$ ,  $^2\text{H}$  (D), and  $^3\text{H}$  (T); C includes any isotopic form of carbon including  $^{12}\text{C}$ ,  $^{13}\text{C}$ , and  $^{14}\text{C}$ ; O includes any isotopic form of oxygen  
30 including  $^{16}\text{O}$ ,  $^{17}\text{O}$  and  $^{18}\text{O}$ ; N includes any isotopic form of nitrogen including  $^{13}\text{N}$ ,  $^{14}\text{N}$  and  $^{15}\text{N}$ ; F includes any isotopic form of fluorine including  $^{19}\text{F}$  and  $^{18}\text{F}$ ; and the like. In one aspect, the compounds of Formula I include isotopes of the atoms covered therein in amounts corresponding to their naturally occurring abundance. However, in certain instances, it may be desirable to enrich one or more atom in a particular isotope which would normally be present in a lower abundance. For example,  $^1\text{H}$  would  
35 normally be present in greater than 99.98% abundance; however, in one aspect, a compound of any formula presented herein may be enriched in  $^2\text{H}$  or  $^3\text{H}$  at one or more positions where H is present. In another aspect, when a compound of any formula presented herein is enriched in a radioactive

5 isotope, for example  $^3\text{H}$  and  $^{14}\text{C}$ , the compound may be useful in drug and/or substrate tissue distribution assays. It is to be understood that the present application encompasses all such isotopic forms.

There is provided a method of treatment of a condition where inhibition of TRPC6 and/or TRPC3 is required, which method comprises administration of a therapeutically effective amount of a  
10 compound of Formula I, or a pharmaceutically acceptable salt thereof, to a person suffering from, or susceptible to, such a condition.

The compounds of Formula I, or pharmaceutically acceptable salts thereof, will normally be administered via the oral route in the form of pharmaceutical preparations comprising the active ingredient or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in a  
15 pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated, the compositions may be administered at varying doses.

The pharmaceutical formulations of the compound of Formula I described above may be prepared for oral administration, particularly in the form of tablets or capsules, and especially involving technologies aimed at furnishing colon-targeted drug release (Patel, M. M. Expert Opin. Drug Deliv.  
20 2011, 8 (10), 1247-1258).

The pharmaceutical formulations of the compound of Formula I described above may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA., (1985).

25 Pharmaceutical formulations suitable for oral administration may comprise one or more physiologically compatible carriers and/or excipients and may be in solid or liquid form. Tablets and capsules may be prepared with binding agents, fillers, lubricants and/or surfactants, such as sodium lauryl sulfate. Liquid compositions may contain conventional additives such as suspending agents, emulsifying agents and/or preservatives. Liquid compositions may be encapsulated in, for example,  
30 gelatin to provide a unit dosage form. Solid oral dosage forms include tablets, two-piece hard shell capsules and soft elastic gelatin (SEG) capsules. Such two-piece hard shell capsules may be made for example by filling a compound of Formula (I) into a gelatin or hydroxypropyl methylcellulose (HPMC) shell.

A dry shell formulation typically comprises of about 40% to 60% w/w concentration of gelatin, about  
35 a 20% to 30% concentration of plasticizer (such as glycerin, sorbitol or propylene glycol) and about a 30% to 40% concentration of water. Other materials such as preservatives, dyes, opacifiers and

5 flavours also may be present. The liquid fill material comprises a solid drug that has been dissolved, solubilized or dispersed (with suspending agents such as beeswax, hydrogenated castor oil or polyethylene glycol 4000) or a liquid drug in vehicles or combinations of vehicles such as mineral oil, vegetable oils, triglycerides, glycols, polyols and surface-active agents.

Suitable daily doses of the compounds of Formula I, or a pharmaceutically acceptable salt thereof, in  
10 therapeutic treatment of humans are about 0.0001-100 mg/kg body weight.

Oral formulations are preferred, particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.1 mg to 1000 mg.

According to a further aspect there is thus provided a pharmaceutical composition comprising a  
15 compound of Formula I, or a pharmaceutically acceptable salt thereof, in admixture with at least one pharmaceutically acceptable adjuvants, diluents and/or carriers.

### Biological Assays

The following test procedures may be employed to determine the inhibitory properties of the compounds described herein.

20 TRPC3 and TRPC6 channel opening causes an influx of predominantly calcium and sodium cations that result in a change in the electrical potential across the cell membrane. This change in membrane potential can be monitored using membrane potential dyes in the following FLIPR™ (Fluorescent Imaging Plate Reader) assays.

### Inhibition of TRPC6 - FLIPR™ Assay

25 TRPC6-HEK293 was purchased from PerkinElmer (PerkinElmer, Product No.: AX-012-C), HEK293 cells were transfected using the pcDNA3.1(+)expression vector containing the coding sequence of the human TRPC6 ion channel. The coding sequence used is identical to coding sequence of GenBank NM\_004621 with the exception of 2 synonym variations (t1683c and c2529t). The cells were grown in DMEM + 10% fetal bovine serum (FBS) + 0.5 mg/mL Geneticin (ion channel expression selection) as  
30 culture medium.

TRPC6 cells were plated at 10K cells/well into 384-well polystyrene plates and then grown for 24 hs at 37°C plus 5% CO<sub>2</sub>. After this time the media was aspirated using a Tecan plate washer and then replaced with 40 µL of dye loading buffer (130 mM NaCl, 5 mM KCl, 0.15 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 20 mM HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)), 5mM NaHCO<sub>3</sub>). For TRPC6, a final

5 concentration of 0.5x is used. Cells with membrane potential dye were then incubated for 30 mins at room temperature prior to beginning the experiments.

To test the effects of compounds on TRPC6 activity, compounds were first diluted in 100% DMSO to 3x the final concentration to be used in the experiments. Typical dose-response experiments ranged from 10  $\mu$ M (top concentration) to 0.5 nM (lowest concentration). Ten microliters of 5x compound in 10 0.5% DMSO were added to 40  $\mu$ L of cells incubated with membrane potential dye. Compound addition was performed on a FLIPRTetra or a FLIPR 384 (MDS Analytical Technologies, Molecular Devices, Sunnyvale, CA, 94089, USA). After a 400 second incubation with compound, 12.5  $\mu$ L of OAG (1-oleoyl-2-acetyl-sn-glycerol (OAG), Sigma, Gillingham, Dorset, SP8 4XT Cat# O6754-10MG) was added at 5x the EC<sub>80</sub> (typical EC<sub>80</sub> for TRPC6 = 3  $\mu$ M final). The OAG challenge is designed to measure the inhibitory 15 activity of compounds on receptor-operated TRPC6 activation.

All data was normalized to low controls (buffer alone) or high controls (OAG EC<sub>100</sub>). Data was analyzed using an XC<sub>50</sub> curve fitting module and reported as pIC<sub>50</sub> or IC<sub>50</sub> values. The values are averaged to determine a mean value, for a minimum of 2 experiments.

#### **Inhibition of TRPC3 – FLIPR™ Assay**

20 AD293 cells were transfected using the PLVX-puro lentivirus vector containing the coding sequence of the human TRPC3 ion channel. Puromycin-resistant cells were selected by treating with 2 $\mu$ g/mL puromycin for two weeks. Monoclonal cells were obtained by limiting dilution and compared for their response to OAG in a membrane potential assay. The cells were grown in DMEM + 10% fetal bovine serum (FBS) +1  $\mu$ g/mL puromycin as culture medium.

25 TRPC3 cells were plated at 9K/well into 384-well polystyrene plates. Cells were grown for 24 h at 37°C plus 5% CO<sub>2</sub> after which media was aspirated using a Tecan plate washer and replaced with 40  $\mu$ L of dye loading buffer (130 mM NaCl, 5 mM KCl, 0.15 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 20 mM HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)), 5mM NaHCO<sub>3</sub>). For TRPC3 a final concentration of 0.5x membrane potential dye (Molecular Devices Membrane Blue, FLIPR Membrane Potential Assay 30 Kit(bulk), Product#R8034(BLUE), Molecular Devices, Sunnyvale, CA, 94089, USA) was used. Cells with membrane potential dye were then incubated for 30 mins at room temperature prior to beginning the experiments.

To test the effects of compounds on TRPC3 activity, compounds were first diluted in 100% DMSO to 3x the final concentration to be used in the experiments. Typical dose-response experiments ranged from 10  $\mu$ M (top concentration) to 0.5 nM (lowest concentration). Ten microliters of 5x compound in 35 0.5% DMSO were added to 40  $\mu$ L of cells incubated with membrane potential dye. Compound addition

5 was performed on a FLIPRTetra or a FLIPR 384 (MDS Analytical Technologies). After a 400 second incubation with compound, 12.5  $\mu$ L of OAG was added at 5x the EC<sub>80</sub> (typical EC<sub>80</sub> for TRPC3 = 2  $\mu$ M final). The OAG challenge is designed to measure the inhibitory activity of compounds on receptor-operated TRPC3 activation.

All data was normalized to low controls (buffer alone) or high controls (OAG EC<sub>100</sub>). Data was analyzed  
10 using an XC<sub>50</sub> curve fitting module and reported as pIC<sub>50</sub> or IC<sub>50</sub> values. The values are averaged to determine a mean value, for a minimum of 2 experiments.

### Electrophysiology assays of TRPC6 and TRPC3 activation

TRPC6 and TRPC3 channel activation results in ionic current which can be measured using the whole-cell patch-clamp technique (see Estacion et al, *J Physiol.* 2006 Apr 15; 572(Pt 2): 359–377 and  
15 Washburn et al, *Bioorg Med Chem Lett.* 2013 Sep 1;23(17):4979-84). 10  $\mu$ M OAG (OAG is a direct activator of TRPC6 and TRPC3 channel) was used to activate human TRPC6 or TRPC3 current in TRPC6 transduced HEK293 cells or TRPC3 transduced AD293 cells, respectively. The TRPC6 or TRPC3 transduced cells were incubated at 37°C and 5% CO<sub>2</sub>. The transduced cells were then detached from the flask using trypsin solution (0.25% trypsin+0.1 % EDTA (ethylenediamine tetraacetic acid)) and  
20 then stored in culture medium for patch-clamp experiments within 5 h. Cells were placed in a small chamber and continuously perfused with an external solution (~3 mL/min) using a RSC-200 perfusion system (Science Instruments, BioLogic). All current recordings are conducted at room temperature (~22°C). Electrodes were made from glass capillary tubes and to give a resistance of 2-4 M $\Omega$  when filled with the respective internal solutions.

25 For TRPC6 current recording, the intracellular solution contained (in mM): 120 CsOH, 120 Aspartate, 20 CsCl, 2 MgCl<sub>2</sub>, 0.4 CaCl<sub>2</sub>, 10 HEPES, 2 Na<sub>2</sub>ATP, 0.1 Na<sub>3</sub>GTP, 10 Glucose, 1 EGTA (pH 7.2-7.25, adjusted with CsOH). The extracellular solution contained (in mM): 145 NaCl, 5 KCl, 1 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 10 Glucose (pH7.4 adjusted with NaOH).

For TRPC3 current recording, the intracellular solution contained (in mM):130 CsCl, 5 HEPES, 5 EGTA,  
30 5 Na<sub>2</sub>ATP, 0.1 Na<sub>3</sub>GTP, 5.5 MgCl<sub>2</sub> (pH 7.2-7.25, adjusted with CsOH). The extracellular solution contained (in mM): 140 NaCl, 4 KCl, 1 MgCl<sub>2</sub>, 10 HEPES, 0.2 CaCl<sub>2</sub>, 10 Glucose, 2 Na<sub>4</sub>EDTA (pH7.4 adjusted with NaOH).

A seal between cell membrane and electrode was made. After whole-cell configuration was established, cell membrane capacitance is cancelled electronically and the series resistance was  
35 compensated by about 70%. TRPC6 or TRPC3 current are induced by a 300 ms voltage ramp protocol (from +100mV to -100mV) every 5 seconds at a holding potential of -60mV. Once the control current

5 was stabilized, the recording chamber was perfused with external solution containing a test compound. At each drug concentration, sufficient time was allowed for the drug effect to reach steady-state.

The TRPC6 or TRPC3 current was measured as the average current at +100 mV. The time course of current was plotted for the whole experiment. Percent inhibition (%) of TRPC6 or TRPC3 was  
 10 calculated from the formula  $\%I = 100 \times (1 - I_D / I_c)$ , where  $I_D$  is the current amplitude measured at the end of a particular drug concentration and  $I_c$  is the control current amplitude measured before drug application. Zero current (background) level is set at the very beginning before OAG activated TRPC6 or TRPC3 current. MultiClamp 700B amplifier with Digidata 1440 interface and pCLAMP software  
 15 (AXON Instruments, Molecular Devices, Sunnyvale, CA, 94089, USA) are used for data acquisition and analysis. The average percent inhibition at each drug concentration is calculated first. Then, the average data is fitted to a logistic function using Prism 6 software to calculate the  $IC_{50}$  values.

**Table 2:** Inhibition of TRPC6 and hTRPC3 as evaluated by FLIPR™ Assay

Example	Name*	TRPC6	TRPC3
		$IC_{50}$ ( $\mu$ M)	$IC_{50}$ ( $\mu$ M)
1	1-[4-(4-fluorophenyl)-2-(triazol-2-yl)cyclopentyl]piperidin-3-amine	<b>0.00337</b>	<b>0.0177</b>
2	1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile	<b>0.00797</b>	<b>0.00831</b>
3	1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-3-carbonitrile	<b>&lt;0.0199</b>	<b>0.0464</b>
4	1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrrole-3-carbonitrile	<b>0.00531</b>	<b>0.00539</b>
5	1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]triazole-4-carbonitrile	<b>0.00378</b>	<b>0.00428</b>
6	1-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile	<b>0.00406</b>	<b>0.00622</b>
7	1-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile	<b>0.0162</b>	<b>0.0175</b>
8	1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine	<b>0.0028</b>	<b>0.00797</b>

9	5-fluoro-1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl] piperidin-3-amine	<b>0.0034</b>	<b>0.00664</b>
10	5-fluoro-1-[4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl) cyclopentyl]piperidin-3-amine	<b>0.0298</b>	<b>0.0160</b>
11	5-fluoro-1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl) cyclopentyl]piperidin-3-amine	<b>0.0106</b>	<b>0.00403</b>
12	1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl] piperidin-3-amine	<b>0.0267</b>	<b>0.00755</b>
13	1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]- 1,2,4-triazole-3-carbonitrile	<b>0.00710</b>	<b>0.0143</b>
14	4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-hydroxy-phenyl) cyclopentoxy]benzonitrile	<b>0.0174</b>	<b>0.0588</b>
15	4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-methoxy-phenyl) cyclopentoxy]benzonitrile	<b>0.00951</b>	<b>0.0225</b>
16	4-[2-(3-amino-1-piperidyl)-4-(3-fluorophenyl) cyclopentoxy]-3-chloro-benzonitrile	<b>0.0193</b>	<b>0.0695</b>
17	4-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]benzonitrile	<b>0.0207</b>	<b>0.0461</b>
18	4-[2-(5-amino-3,3-difluoro-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]benzonitrile	<b>0.0311</b>	<b>0.0425</b>
19	4-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]-2-fluoro-benzonitrile	<b>0.0251</b>	<b>0.0645</b>
20	2-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy] benzonitrile	<b>0.0141</b>	<b>0.0388</b>
21	4-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy]-3- chloro-benzonitrile	<b>0.0174</b>	<b>0.0723</b>
22	6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]-5-methyl-pyridazine-3-carbonitrile	<b>0.0288</b>	<b>0.118</b>
23	1-[2-(4-chloropyridazin-3-yl)oxy-4-(4-fluorophenyl) cyclopentyl]piperidin-3-amine	<b>0.00656</b>	<b>0.0113</b>
24	6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]pyridazine-3-carbonitrile	<b>&gt;0.0118</b>	<b>0.00720</b>

25	1-[4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yl)oxy-cyclopentyl]piperidin-3-amine	<b>0.00993</b>	<b>0.209</b>
26	6-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]pyridine-3-carbonitrile	<b>0.00951</b>	<b>0.0255</b>
27	6-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]pyridine-3-carbonitrile	<b>0.0220</b>	<b>0.0507</b>
28	1-[4-(4-fluorophenyl)-2-pyridazin-3-yloxy-cyclopentyl] piperidin-3-amine	<b>0.0178</b>	<b>0.0322</b>
29	5-fluoro-1-[4-(4-fluorophenyl)-2-pyrimidin-4-yloxy-cyclopentyl]piperidin-3-amine	<b>0.00344</b>	<b>0.00368</b>
30	2-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]pyrimidine-5-carbonitrile	<b>0.0115</b>	<b>0.0240</b>
31	5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]pyrazine-2-carbonitrile	<b>0.0137</b>	<b>0.0255</b>
32	5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl) cyclopentoxy]pyrimidine-2-carbonitrile	<b>0.0106</b>	<b>0.0392</b>

5 \* Data are presented for the most potent isolated isomer of each compound.

As can be seen from the table above the compound of the present disclosure is a highly active inhibitor of both TRPC6 and TRPC3, with inhibitory activity in the assays used in the sub-30nM range. This ability to inhibit both TRPC6 and TRPC3 may have therapeutic importance as the degree of selectivity may provide enhanced therapeutic efficacy relative to a selective inhibitor of either of these group 3 canonical Transient receptor potential channels. As noted above, TRPC3 and TRPC6 have high sequence homology and belong to the group 3 canonical Transient receptor potential channel grouping. The compound of the present disclosure thus has promise as therapeutic agent for the treatment or prophylaxis of diseases and conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial, for example kidney disease and, in particular, focal segmental glomerulosclerosis (FSGS).

#### 15 **Process for preparation of compounds**

Compounds of the specification can be prepared as described below. For example, Compound 10 can be prepared from 1-(cyclopent-3-enyl)-4-fluorobenzene starting material, itself available from olefin metathesis of 1-fluoro-4-(hepta-1,6-dien-4-yl)benzene. Oxidation of the cyclopentene, with any suitable oxidant such as m-CPBA or hydrogen peroxide in formic acid, provides an epoxide intermediate that can undergo nucleophilic ring opening with a piperidine nucleophile to afford a

5 cyclopentanol derivative. The cyclopentanol derivative can then be transformed by Mitsunobu reaction to give a 1*H*-1,2,4-triazol-1-yl derivative. The final products are then obtained by Boc deprotection under acidic conditions. Full details of one synthesis of the final compounds are provided below. The various possible isomeric products obtained in each synthetic step can be separated by chromatography, for example preparative HPLC, such as preparative chiral HPLC or SFC. Suitable  
10 columns for use in these standard techniques and the corresponding eluent systems are provided below.

### Examples

The compounds of the application will now be further explained by reference to the following non-limiting examples.


15 <sup>1</sup>H NMR measurements were performed on Bruker Avance spectrometers, operating at <sup>1</sup>H frequencies of 300 and 400MHz, respectively. The experiments were typically recorded at 25°C. Chemical shifts are given in ppm with the solvent as internal standard. HPLC was generally performed on Shimadzu UHPLC coupled with DAD detector, ELSD detector and 2020EV MS, or Shimadzu UFLC  
20 coupled with DAD detector, ELSD detector and 2020EV MS. Flash chromatography was performed using straight phase flash chromatography on a SP1™ Purification system from Biotage™ using normal phase silica FLASH+™ (40M, 25M or 12 M) or SNAP™ KP-Sil Cartridges (340, 100, 50 or 10), with C18-  
flash columns or standard flash chromatography. In general, all solvents used were commercially available and of analytical grade. Anhydrous solvents were routinely used for reactions. Phase Separators used in the examples are ISOLUTE® Phase Separator columns. The intermediates and  
25 examples named below were named using ACD/Name 12.01 from Advanced Chemistry Development, Inc. (ACD/Labs). The starting materials were obtained from commercial sources or made via literature routes. For example, tert-butyl ((3*R*,5*R*)-5-fluoropiperidin-3-yl)carbamate was purchased from PharmaBlock Inc, 10 Xuefu Road, Nanjing Hi-Tech Zone, China.

The following abbreviations are used: AcOH = acetic acid; aq = aqueous; Boc<sub>2</sub>O = di-*tert*-butyl  
30 decarbonate; Boc = *t*-butyloxycarbonyl; br = broad; CDCl<sub>3</sub> = deuterated chloroform; CD<sub>3</sub>OD = deuterated methanol; CH<sub>3</sub>NO<sub>2</sub> = nitromethane; d = doublet; δ = chemical shift in NMR relative to tetramethyl silane; DCE = 1,2-dichloroethane; DCM = dichloromethane; DEA = diethylamine; DEAD = diethyl azodicarboxylate; DIPEA = *N,N*-diisopropylethylamine; DMAP = 2,6-dimethylaminopyridine; DMF = *N,N*-dimethylformamide; DMSO = dimethylsulfoxide; DMSO-d<sub>6</sub> = deuterated  
35 dimethylsulfoxide; DPPA = diphenyl phosphorazidate; dppf = 1,1'-bis(diphenylphosphino)ferrocene; DIAD = Di-isopropyl (E)-diazene-1,2-dicarboxylate; DSC = differential scanning calorimetry; DTAD = Di-*tert*-butyl (E)-diazene-1,2-dicarboxylate; ee = enantiomeric excess; eq. = equivalent; ESI =

5 electro spray ionization; Et<sub>2</sub>O = diethyl ether; EtOAc or EA = ethylacetate; EtOH = ethanol; FA = formic acid; Grubbs catalyst (1,3-Dimesitylimidazolin-2-ylidene)(tricyclohexylphosphine)ruthenium dichloride; h = hour(s); HATU = (dimethylamino)-*N,N*-dimethyl(3-oxido-1*H*-[1,2,3]triazolo[4,5-*b*]pyridinyl)methaniminium hexafluorophosphate; HCl = hydrochloric acid; H<sub>2</sub>O<sub>2</sub> = hydrogen peroxide; HP = high pressure; IPA = isopropylalcohol; LC = liquid chromatography; LiClO<sub>4</sub> = lithium perchlorate; m = multiplet; mmol = millimole; mCPBA = meta-chloroperoxybenzoic acid; MeOH = methanol; min = minute(s); MeCN = acetonitrile; MeNO<sub>2</sub> = nitromethane; MS = mass = spectrometry; NMP = *N*-methyl-2-pyrrolidone; NMR = nuclear magnetic resonance; Pd<sub>2</sub>dba<sub>3</sub> = Tris(dibenzylideneacetone)dipalladium (0); Pd(dppf)Cl<sub>2</sub> = 1,1'-bis(di-*tert*-butylphosphino)ferrocene palladium dichloride; PE = Petroleum ether; PPh<sub>3</sub> = Triphenylphosphine; q = quartet; rt = room temperature; Rt or RT = retention time; s = singlet; sat = saturated; SFC = supercritical fluid chromatography; t = triplet; T3P = 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide; TBTU = 2-(1*H*-benzo[*d*][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium tetrafluoroborate; TFA = trifluoroacetic acid; THF = tetrahydrofuran; TLC = thin layer chromatography; TMS = trimethylsilyl; Xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene.

## 20 Synthesis of Starting Materials and Intermediates

### Hepta-1,6-dien-4-ylbenzene **D1**



A solution of CH<sub>3</sub>NO<sub>2</sub> (25.8 g) in DCM (400 mL) was treated with TiCl<sub>4</sub> solution (151 mL, 151 mmol, 1.0 M in DCM) at -60°C, then benzaldehyde (10 g, 94.2 mmol) in DCM (50 mL). The reaction was stirred at -60°C for 0.5 h, then cooled to -78°C prior to dropwise addition of allyltrimethylsilane (32 g, 282 mmol in DCM (50 mL). The reaction mixture was stirred at -78°C for 2h and -60°C for 6h, then poured into saturated NH<sub>4</sub>Cl solution (500 mL) and extracted with dichloromethane (300 mL x 2). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated. The residue was purified by column chromatography (petroleum ether) on silica gel to give hepta-1,6-  
30 dien-4-ylbenzene **D1** (13.7 g, 84 % yield) as colourless oil.

### 1-Fluoro-4-(hepta-1,6-dien-4-yl)benzene **D2**

TiCl<sub>4</sub> (56.9 mL, 0.516 mol) was added to MeNO<sub>2</sub> (69.5 mL, 1.29 mol) in DCM (1.5 L) at -78°C over a period of 20 minutes under an N<sub>2</sub> atmosphere. The resulting mixture was stirred for 20 min and then

- 5 treated with 4-fluorobenzaldehyde (40 g, 0.322 mol) in a dropwise manner over a period of 20 min. The resulting mixture was stirred at -70 °C for 1 h, then treated with allyltrimethylsilane (110 g, 0.967 mol) over a period of 0.5h. The resulting mixture was stirred at -70 °C for 3 h and then warmed to 25°C. The reaction mixture was quenched with ice/water (1 L), extracted with DCM (3 x 400 mL), and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated to afford pale yellow oil.
- 10 Silica gel flash chromatography, (0 to 5% EtOAc in pentane) gave 1-fluoro-4-(hepta-1,6-dien-4-yl)benzene (55.0 g, 90 %) as a colourless oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.14 (2H, m), 6.98 (2H, m), 5.65 (2H, ddt), 5.01 - 4.83 (4H, m), 2.72 (1H, tt), 2.51 - 2.18 (4H,m).


#### 1-Fluoro-3-(hepta-1,6-dien-4-yl)benzene **D3**

- TiCl<sub>4</sub> (56.9 mL, 515.65 mmol), MeNO<sub>2</sub> (69.5 mL, 1289.13 mmol) in DCM (1500 mL) were reacted with  
15 3-fluorobenzaldehyde (40 g, 322.28 mmol) and allyltrimethylsilane (110 g, 966.85 mmol) at -78°C as described for the synthesis of D1. Following work up, chromatography (Silica, 0 to 5% EtOAc in pentane) afforded 1-fluoro-3-(hepta-1,6-dien-4-yl)benzene **D3** as a colourless oil which was used without further purification.

#### 1-Fluoro-4-(hepta-1,6-dien-4-yl)-2-methoxybenzene **D4**

- 20 A solution of nitromethane (5.7 g, 4.5 eq.) in DCM (80 mL) and TiCl<sub>4</sub> (33.3 mL, 1.6 eq., 1M in DCM) was reacted with 4-fluoro-3-methoxybenzaldehyde (3.5 g, 1.0 eq.) in 20 mL DCM then allyltrimethylsilane (7.2 g, 3.0 eq.) as described for the synthesis of D1. Column chromatography (silica gel, petroleum ether) afforded 1-fluoro-4-(hepta-1,6-dien-4-yl)-2-methoxybenzene **D4** (6.5 g, 98% yield) as yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400MHz) δ 7.00 (1H, dd), 6.76 (1H, dd), 6.73-6.67 (1H, m), 5.71-5.65 (2H, m), 5.02-4.95  
25 (4H, m), 3.91 (3H, s), 2.72-2.67 (1H, m), 2.44-2.33 (4H, m).

#### Cyclopent-3-enylbenzene **C1**



- To a solution of **D1** (13.7 g) in DCM (100 mL) was added Grubbs catalyst (1.0 g, 0.015 eq). The mixture was stirred at rt under nitrogen overnight at which stage TLC indicated no starting material remained.
- 30 The reaction mixture was then washed with water (200 mL), brine (200 mL), then dried and evaporated. Column chromatography (n-heptane) on silica gel gave cyclopent-3-enylbenzene **C1** (6.1 g, 55 % yield) as colourless oil.

#### 1-(Cyclopent-3-enyl)-4-fluorobenzene **C2**

- Grubbs catalyst (2.68 g, 3.15 mmol) was added to 1-fluoro-4-(hepta-1,6-dien-4-yl)benzene (50 g, 0.263  
35 mol) in DCM (500 mL) at 0°C over a period of 20 min under nitrogen. The resulting mixture was stirred

5 at 25 °C for 15 h. The solvent was removed under reduced pressure and the residue purified by column chromatography (0 to 5% EtOAc in petroleum ether) to afford 1-(cyclopent-3-en-1-yl)-4-fluorobenzene **C2** (30.0 g, 70.4 %) as a colourless liquid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.24 (2 H, m), 6.97 (2 H, m), 5.78 (2 H, d), 3.46 (1 H, tt), 2.81 (2 H, m), 2.40 (2 H, m).

#### 1-(Cyclopent-3-enyl)-3-fluorobenzene **C3**


10 1-Fluoro-3-(hepta-1,6-dien-4-yl)benzene (3.5 g) in DCM (40 mL) was reacted with Grubbs catalyst (230 mg, 0.015 eq) as described for the synthesis of C1. Column chromatography (n-heptane) give **C3** (2.1 g, 70%) as colourless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400MHz) δ 7.26-7.24 (1H, m), 7.04-6.88 (3H, m), 5.80-5.75 (2H, m), 3.49-3.45 (1H, m), 2.87-2.81 (2H, m), 2.48-2.41 (2H, m).

#### 4-(cyclopent-3-enyl)-1-fluoro-2-methoxybenzene **C4**

15 1-Fluoro-4-(hepta-1,6-dien-4-yl)-2-methoxybenzene **D4** (4.5 g, 1.0 eq.) in 50 mL DCM was reacted with was added Grubbs catalyst (450 mg, 0.025 eq.) as described for the synthesis of C1. Column chromatography on silica gel (Petroleum ether) gave 4-(cyclopent-3-enyl)-1-fluoro-2-methoxybenzene (3.1 g, 79% yield) as brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400MHz) δ 6.99-6.94 (1H, m), 6.85 (1H, dd), 6.76-6.62 (1H, m), 5.78 (2H, s), 3.88 (3H, s), 3.44-3.38 (1H, m), 2.82 (2H, dd), 2.45-2.38 (2H, m).

20 m).

#### 3-Phenyl-6-oxabicyclo[3.1.0]hexane **E1**



To a solution of cyclopent-3-enylbenzene **C1** (6.1 g, 42.3 mmol) in DCM (80 mL) was added mCPBA (12.8 g, 1.5 eq, 85%) at 0°C in a portionwise manner. The mixture was stirred at rt overnight. Saturated  
 25 NaHSO<sub>3</sub> solution (400 mL) was then added and the suspension was stirred at rt for 30min. The suspension was then diluted with water (200 mL), extracted with dichloromethane (200 mL) and the organic layer was washed with saturated sodium bicarbonate solution and brine. The combined organics were dried over anhydrous sodium sulfate, filtered and evaporated. The residue was purified  
 30 by column chromatography (petroleum ether/EtOAc 20:1) on silica gel to afford 3-phenyl-6-oxabicyclo[3.1.0]hexane **E1** (4.9 g, 73% yield) as colourless oil.

#### trans-3-(4-fluorophenyl)-6-oxabicyclo[3.1.0]hexane **E2**



5 Formic acid (88%) (392 mL, 9.15 mol) was added dropwise to H<sub>2</sub>O<sub>2</sub> (30%) (262 mL, 2.62 mol) cooled to 0°C over a period of 1 h under air. 1-(Cyclopent-3-en-1-yl)-4-fluorobenzene **C2** (20 g, 0.123 mol) in DCM (250 mL) was then added at 0°C over a period of 3 h under air. The resulting mixture was then stirred at ambient temperature for 12 h, after which the solvent was then removed under reduced pressure. The crude product was purified by flash silica chromatography, (0 to 10% EtOAc in petroleum ether) to afford *trans*-3-(4-fluorophenyl)-6-oxabicyclo[3.1.0]hexane **E2** (12.00 g, 54.6 %) as a colourless oil. 1H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.15 (2H, m), 6.99 (2 H, m), 3.60 (2H, s), 2.98 (1H, tt), 2.46 (2H, dd), 1.71 (2H, dd).


### 3-(3-Fluorophenyl)-6-oxabicyclo[3.1.0]hexane **E3**

15 1-(Cyclopent-3-enyl)-3-fluorobenzene **C2** (2.1 g) in DCM (50 mL) and mCPBA (3.3 g, 1.5 eq, 85%) were reacted as described for the synthesis of **E1**. Silica gel chromatography (petroleum ether/EtOAc = 20:1) gave **E3** (1.1 g, 47%) as a colourless oil.

### 3-(4-fluoro-3-methoxyphenyl)-6-oxabicyclo[3.1.0]hexane **E4**

mCPBA (5.57 g, 2.0 eq.) and 4-(cyclopent-3-enyl)-1-fluoro-2-methoxybenzene **C4** (3.1 g, 1.0 eq.) in 50 mL dichloromethane were reacted as described for the synthesis of **E1**. Column chromatography gave **E4** as the *trans* isomer (1.3 g, 47% yield) and the *cis* isomer (300 mg, 9% yield) as colourless oils. *Trans*-**E4** 1H NMR (CDCl<sub>3</sub>, 400MHz) δ 7.00-6.95 (1H, m), 6.77 (1H, dd), 6.72-6.66 (1H, m), 3.87 (3H, s), 3.58 (2H, s), 2.98-2.91 (1H, m), 2.47-2.41 (2H, m), 1.71 (2H, dd). *cis*-**E4** 1H NMR (CDCl<sub>3</sub>, 400MHz) δ 6.99 (1H, dd), 6.92 (1H, dd), 6.75-6.73 (1H, m), 3.89 (3H, s), 3.57 (2H, s), 3.45-3.39 (1H, s), 2.33 (2H, dd), 2.08 (2H, dd).

25 *tert*-butyl (3*R*)-1-(2-hydroxy-4-phenylcyclopentyl)piperidin-3-ylcarbamate **F1**




To a solution of 3-phenyl-6-oxabicyclo[3.1.0]hexane **E1** (1.5 g) in CH<sub>3</sub>CN (20 mL) was added (*R*)-*tert*-butyl piperidin-3-ylcarbamate (2.2 g, 1.2 eq) and LiClO<sub>4</sub> (2.0 g, 2.0 eq). The resulting suspension was refluxed overnight then cooled and filtered. The filtrate was evaporated and the residue was purified by column chromatography (petroleum ether/EtOAc 1:1) on silica gel to give *tert*-butyl (3*R*)-1-(2-hydroxy-4-phenylcyclopentyl)piperidin-3-ylcarbamate **F1** (1.97 g, 59 %) as yellow solid which was used without further purification.

*tert*-butyl (3*R*)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2a**

5 (R)-1,1'-Bi-2-naphthol (1.607 g, 5.61 mmol) in toluene (50 mL), was treated with dibutylmagnesium (7.29 mL, 1.0M, 7.29 mmol in n-heptane) at 25°C. After 0.5h stirring, the reaction was cooled to 0°C and then trans-3-(4-fluorophenyl)-6-oxabicyclo[3.1.0]hexane **E2** (10 g, 56.11 mmol) and tert-butyl (R)-piperidin-3-ylcarbamate (11.24 g, 56.11 mmol) in toluene (150 mL) were added. After overnight stirring, the reaction mixture was poured into crushed ice, the mixture partitioned between DCM and  
 10 water. The aqueous layer was extracted again with DCM and the combined organic layers were washed with saturated NaHCO<sub>3</sub> and brine, then dried (sodium sulfate) and evaporated. Flash silica chromatography (0 to 10% MeOH in DCM) gave tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2b** (12.00 g, 56.5 %) as a yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.20 (2H, ddt), 6.94 - 7.07 (2H, m), 4.94 (1H, s), 4.32 (1H, t), 3.78 (1H, s), 3.31 (1H, dtd), 2.72  
 15 (2H, dd), 2.53 (2H, s), 2.24 (1H, dt), 1.96 - 2.10 (2H, m), 1.52 - 1.86 (4H, m), 1.47 (10H, d). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 379.

*tert-butyl N-[(3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-hydroxy-cyclopentyl]-3-piperidyl]carbamate and tert-butyl N-[(3R,5R)-5-fluoro-1-[(1S,2S,4R)-4-(4-fluorophenyl)-2-hydroxy-cyclopentyl]-3-piperidyl]carbamate **F2b***



Trans-3-(4-fluorophenyl)-6-oxabicyclo[3.1.0]hexane **E2** (1.225 g, 6.87 mmol) was added to tert-butyl ((3R,5R)-5-fluoropiperidin-3-yl)carbamate (1 g, 4.58 mmol), and Na<sub>2</sub>CO<sub>3</sub> (1.457 g, 13.74 mmol) in EtOH (10 mL) at rt. The resulting mixture was stirred at 90 °C for 12 h. The solvent was then removed under reduced pressure and the crude product was purified by silica gel flash column chromatography (0 to  
 25 10% MeOH in DCM) to give a mixture of the above named stereoisomers, **F2b**, (1.030 g, 56.7 %) as a yellow oil. LCMS: m/z (ES+), [M+H]<sup>+</sup> = 397.

*tert-butyl 4,4-difluoro-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2c***

A mixture of trans 3-(4-fluorophenyl)-6-oxabicyclo[3.1.0]hexane **E2** (450 mg, 1.2 eq.), tert-butyl 4,4-difluoropiperidin-3-ylcarbamate (500 mg, 1.0 eq.) and Na<sub>2</sub>CO<sub>3</sub> (450 mg, 2.0 eq.) in ethanol (8 mL) was  
 30 stirred under microwave condition: 130°C, 16h. The mixture was diluted with dichloromethane and

5 filtered the filtrate concentrated and the residue was purified by silica gel flash column chromatography (petroleum ether/EtOAc 90:10 to 60:40) to give tert-butyl 4,4-difluoro-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2c** (250 mg, 28% yield) as light yellow thick oil.

*tert-butyl (3R)-5,5-difluoro-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate F2d*

10 To a solution of (1R,3S,5S)-3-(4-fluorophenyl)-6-oxabicyclo[3.1.0]hexane (trans epoxide) **E2** (300 mg, 1.0eq.) in 10 mL anhydrous ethanol was added (R)-tert-butyl 5,5-difluoropiperidin-3-ylcarbamate (398 mg, 1.0 eq.) and sodium carbonate (357 mg, 2.0 eq.) in a sealed vial. The suspension was irradiated in microwave at 130°C for 7h. The suspension was filtered and concentrated. The residue was purified by column on silica gel (petroleum ether/EtOAc, 0 to 10% gradient then 20% EtOAc in DCM) to afford  
15 compound tert-butyl (3R)-5,5-difluoro-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2d** (290 mg, 42 % yield) as white solid.

*tert-butyl (3R)-1-(4-(3-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate F3*

To a solution of 3-(3-fluorophenyl)-6-oxabicyclo[3.1.0]hexane **E3** (300 mg) in CH<sub>3</sub>CN (10 mL) was added (R)-tert-butyl piperidin-3-ylcarbamate (404 mg, 1.2 eq), LiClO<sub>4</sub> (358 mg, 2.0 eq). The reaction  
20 mixture was refluxed overnight. TLC showed the starting material was consumed completely. The mixture was concentrated and the residue was added ethyl acetate (50 mL) and water (50 mL). The mixture was extracted with ethyl acetate. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by silica gel column chromatography eluted with ethyl acetate to give tert-butyl (3R)-1-(4-(3-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F3** (580 mg, 90%).

25 *tert-butyl (3R)-1-(4-(4-fluoro-3-methoxyphenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate F4*

To a solution of 3-(4-fluoro-3-methoxyphenyl)-6-oxabicyclo[3.1.0]hexane **E4** (100 mg, 1.0 eq.) in 3 mL anhydrous ethanol was added (R)-tert-butyl piperidin-3-ylcarbamate (115 mg, 1.2 eq.) and sodium carbonate (101 mg, 2.0eq.) in a sealed vial. The suspension was irradiated in microwave at 130°C for 6h. The suspension was filtered and concentrated. Column chromatography on the residue (silica gel  
30 DCM/methanol, 0 to 3% methanol) gave **F4** (140 mg, 71% yield) as colourless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400MHz) δ 6.99 (1H, dd), 6.86 (1H, dd), 6.75-6.71 (1H, m), 4.92 (1H, br s), 4.27-4.21 (1H, m), 3.89 (3H, s), 3.75 (1H, br s), 3.10-3.06 (2H, m), 2.88-2.75 (2H, m), 2.53 (2H, m), 2.41-2.35 (2H, m), 2.15-2.05 (1H, m), 1.90-1.66 (6H, m), 1.40 (9H, d).


### Compound 1

35 *Step 1. tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-(2H-1,2,3-triazol-2-yl)cyclopentyl)piperidin-3-ylcarbamate*

5 A solution of trans tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2a** (600 mg, 1.59 mmol), 1H-1,2,3-triazole (219 mg, 3.17 mmol), DIAD (0.401 mL, 2.06 mmol) and PPh<sub>3</sub> (541 mg, 2.06 mmol) in DCM (20 mL) were stirred at rt for 2 hours. The solvent was removed under reduced pressure and the residue purified by silica gel flash column chromatography, (10 to 50% MeCN in water) to afford the title compound (450 mg, 66.1 %) as a white solid. The crude product was separated on a Waters SFC 350 Preparative System [Column: CHIRALART Amylose-SA, 2x25cm, 5μm; Mobile Phase A: CO<sub>2</sub>: 80, Mobile Phase B: MeOH (2mM NH<sub>3</sub>-MeOH): 20; Flow rate: 40 mL/min; 220 nm]. Two fractions were obtained as white solids: fraction 1 (300 mg, 66.7 %, RT1:3.03) and fraction 2 (100 mg, 22.22 %, RT2:4.58).

15 Fraction 1 was further separated on a Waters SFC 350 Preparative System, Column: (R,R)-WHELK-O1-Kromasil, 5cm x 25cm (5μm); Mobile Phase A: CO<sub>2</sub>: 85, Mobile Phase B: MeOH (2mM NH<sub>3</sub>-MeOH):15; Flow rate: 40 mL/min; 220 nm; RT1:2.31; RT2:2.71. The fractions containing the desired compound were evaporated to dryness to afford isomer 1 (120 mg, 40 %, 100% ee) and isomer 2 (120 mg, 40 %, 98.4% ee) as white solids. LCMS m/z (ESI), [M+H]<sup>+</sup> = 430.

*Step 2. 1-[4-(4-fluorophenyl)-2-(triazol-2-yl)cyclopentyl]piperidin-3-amine* **Compound 1**




20 A solution of isomer 1 (120 mg, 0.28 mmol) obtained in step 1 in TFA (1 mL) and DCM (5 mL) was stirred at rt for 1h. The solvent was then removed under reduced pressure and the crude product was purified by preparative HPLC [Column: XBridge Prep OBD C18 Column 30x150mm 5μm; Mobile Phase A: Water (containing 10 mmol/L NH<sub>4</sub>HCO<sub>3</sub> + 0.1% aq. NH<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 60 mL/min; Gradient: 25% B to 54% B in 8 min; 254/220 nm; Rt: 6.87 min] to afford **Compound 1** (70.0 mg, 76 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 330; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.71 (2H, s), 7.31 (2H, ddd), 7.10 - 6.96 (m, 2H), 5.23 (1H, ddd), 3.58 (2H, ddt), 3.08 - 2.72 (3H, m), 2.52 - 2.17 (3H, m), 1.86 (4H, ddd), 1.75 - 1.45 (2H, m), 1.11 (1H, qd). <sup>19</sup>F NMR (300MHz, CD<sub>3</sub>OD, 24°C) δ -118.73 (s, 1F).

30 **Compound 2**

*Step 1. tert-butyl (3R)-1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl carbamate*

5 To a mixture of tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2a** (5 g, 13.21 mmol), 1H-pyrazole-4-carbonitrile (1.230 g, 13.21 mmol), PPh<sub>3</sub> (5.20 g, 19.82 mmol) in DCM (100 mL) was added DTAD (4.56 g, 19.82 mmol). The reaction was stirred at 25 °C for 16 hours. The resulting solution was washed with sat. NaHCO<sub>3</sub> and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, then concentrated to dryness. The residue was purified by C18 flash column chromatography (elution gradient 40 to 55% MeCN in water (with 0.2% ammonia) to afford the desired product as a yellow oil. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 454. Separation by preparative chiral-HPLC [Chiralpak IA, 2x25cm, 5 μm; Mobile Phase A: Hexanes-HPLC, Mobile Phase B: IPA-HPLC; Flow rate: 20 mL/min; Gradient: A:B = 70:30, 17.5 min] gave the title compound (isomer 1, 2.60 g, 47.3 %) as a yellow oil.

15 *Step 2. 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile Compound 2*



To isomer 1 obtained in step 1 (2.6 g, 5.73 mmol) was added to HCl in dioxane (50 mL, 200 mmol). The resulting mixture was stirred at 20 °C for 4 hours, then concentrated to dryness. The residue was treated with Et<sub>2</sub>O/MeOH (10/1) and the resultant solid was collected, then treated with diluted with sat. Na<sub>2</sub>CO<sub>3</sub> and then extracted into EtOAc. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness to give **Compound 2** (1.358 g, 67.0 %) as a light-yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 8.74 (1 H, s), 8.11 (1 H, s), 7.30 - 7.43 (2 H, m), 7.05 - 7.20 (2 H, m), 4.87 - 5.00 (1 H, m), 3.26 - 3.41 (2 H, m), 2.79 (1 H, d), 2.50 - 2.72 (2 H, m), 2.09 - 2.32 (3 H, m), 1.96 (1 H, dd), 1.50 - 1.79 (4 H, m), 1.37 (3 H, d), 0.83 - 1.02 (1 H, m). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 354.


25 **Compound 3**

*Step 1. tert-butyl (3R)-1-(2-(3-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl) piperidin-3-yl carbamate*

DTAD (243 mg, 1.06 mmol) was added dropwise to **F2a** (200 mg, 0.53 mmol), 1H-pyrazole-3-carbonitrile (49.2 mg, 0.53 mmol) and PPh<sub>3</sub> (277 mg, 1.06 mmol) in DCM (15 mL) at 0°C under nitrogen. The resulting mixture was stirred at 25 °C for 3 hours. The organic layer was washed with NaHCO<sub>3</sub> aq and the solvent was removed under reduced pressure. The crude product was purified by reverse phase chromatography (C18 column) using decreasingly polar mixtures of water (containing 0.1% NH<sub>3</sub>)

5 and MeCN as eluent. Fractions containing the desired compound were evaporated to dryness to afford tert-butyl (3R)-1-(2-(3-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate (240 mg, 100 %) as a white solid. This solid was purified by preparative TLC (DCM: MeOH = 40: 1), to afford tert-butyl ((3R)-1-(2-(3-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl)carbamate fraction 1 (90 mg, 37.5 %) as a yellow solid and tert-butyl ((3R)-1-(2-(3-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl)carbamate fraction 2 (70.0 mg, 29.2 %) as a yellow solid. LCMS for both fraction: m/z (ESI), [M+H]<sup>+</sup> = 454; Fraction 1 (90 mg, 0.20 mmol) was purified by preparative chiral-HPLC [ Chiralpak IE column, eluting isocratically with 5% IPA in Hexanes (modified with 0.1% DEA) as eluent to afford tert-butyl ((3R)-1-(2-(3-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl)carbamate isomer 1 (35.0 mg, 38.9 %, isomer 1, 99.3% ee) as a yellow solid and isomer 2 (30.0 mg, 33.3 %, isomer 2, 99% ee) as a yellow solid. LCMS: (isomer 1) m/z (ESI), [M+H]<sup>+</sup> = 454; (isomer 2) m/z (ESI), [M+H]<sup>+</sup> = 454.

*Step 2. 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-3-carbonitrile **Compound 3***




TFA (0.5 mL, 6.49 mmol) was added to above tert-butyl ((3R)-1-(2-(3-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl)carbamate isomer 1 (20 mg, 0.04 mmol) in DCM (3 mL). The resulting mixture was stirred at 25 °C for 2 hours. Preparative HPLC Column [X Select CSH Prep C18 OBD Column, 5μm, 19\*150mm; Mobile Phase A: Waters (0.05% TFA), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 12% B to 32% B in 7 min; 254; 220 nm] **Compound 3**, isomer 1, (17.00 mg, 51.8 %) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.75 (dd, 1H), 7.28 - 7.42 (m, 2H), 6.96 - 7.14 (m, 3H), 5.17 (ddd, 1H), 3.81 (dt, 1H), 3.60 (s, 1H), 3.41 (dt, 2H), 3.14 (d, 1H), 2.67 (s, 1H), 2.29 - 2.63 (m, 5H), 1.90 (dt, 2H), 1.44 - 1.74 (m, 2H). <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD) δ -77.287(m, 10F), -118.609 (s, 1F). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 354.

**Compound 4**

*Step 1. tert-butyl (3R)-1-(2-(3-cyano-1H-pyrrol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate*

5 To a solution of tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2a** (250 mg, 0.66 mmol), 1H-pyrrole-3-carbonitrile (60.8 mg, 0.66 mmol), PPh<sub>3</sub> (346 mg, 1.32 mmol) in DCM (15 mL), was reacted with DTAD (304 mg, 1.32 mmol) as described for the synthesis of compound 3 above. C18 flash column chromatography, elution gradient 20 to 60% MeCN in water (with 0.3% NH<sub>3</sub>H<sub>2</sub>O) delivered tert-butyl (3R)-1-(2-(3-cyano-1H-pyrrol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate (180 mg, 60.2 %) as a colourless oil. Preparative chiral-HPLC [Phenomenex Lux 5u Cellulose-4, AXIA Packed, 250\*21.2mm, 5 μm; Mobile Phase A: Hexanes--HPLC, Mobile Phase B: IPA--HPLC; Flow rate: 20 mL/min; Gradient: A:B = 80:20 in 21 min; 254/220 nm; RT1:12.5; RT2:17.2 afforded tert-butyl (3R)-1-(2-(3-cyano-1H-pyrrol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate isomer 1 (70.0 mg, 38.9 %, isomer 1) as a yellow oil and tert-butyl (3R)-1-(2-(3-cyano-1H-pyrrol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate isomer 2 (70.0 mg, 38.9 %, isomer 2) as a yellow oil. LCMS for both isomers: m/z (ESI), [M+H]<sup>+</sup> = 453.

*Step 2. 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrrole-3-carbonitrile **Compound 4***




20 TFA (1 mL, 12.98 mmol) was added to the above tert-butyl (3R)-1-(2-(3-cyano-1H-pyrrol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate isomer 2 (70 mg, 0.18 mmol) in DCM (5 mL). The resulting mixture was stirred at 25 °C for 2 hours. Standard work-up, then preparative HPLC [XBridge Prep OBD C18 Column 30×150mm 5 μm; Mobile Phase A: Waters (10mmol/L NH<sub>4</sub>HCO<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 35% B to 39% B in 35 min; 254/220 nm) gave **Compound 4**, isomer 2 (20.00 mg, 24.25 %) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.36 (dtd, 2H), 1.50 - 1.93 (m, 3H), 2.13 - 2.45 (m, 5H), 2.63 (dt, 1H), 2.86 - 2.97 (m, 1H), 3.05 (dq, 1H), 3.33 - 3.56 (m, 2H), 4.71 (ddt, 1H), 6.48 (dd, 1H), 6.98 - 7.12 (m, 3H), 7.27 - 7.40 (m, 2H), 7.66 (t, 1H). <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD) δ -76.962 (m, 3F), -119.017 (s, 1F). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 353.

**Compound 5**

30 *Step 1. tert-butyl (3R)-1-(2-(4-cyano-1H-1,2,3-triazol-1-yl)-4-(4-fluorophenyl)cyclopentyl) piperidin-3-ylcarbamate*

- 5 A Mitsunobu reaction of **F2a** (350 mg, 0.92 mmol), 1H-1,2,3-triazole-4-carbonitrile (87 mg, 0.92 mmol), PPh<sub>3</sub> (485 mg, 1.85 mmol) in DCM (15 mL) and DTAD (426 mg, 1.85 mmol) was performed as described for the synthesis of compound 3 above. Flash C18 column chromatography [elution gradient 20 to 60% MeCN in water (with 0.3% aq. NH<sub>3</sub>)] gave a colourless oil (220 mg, 52.3 %).
- Preparative chiral-HPLC on this oil [Phenomenex Lux 5u Cellulose-4, AXIA Packed, 250\*21.2mm, 5µm; Mobile Phase A: Hexanes--HPLC, Mobile Phase B: IPA--HPLC; Flow rate: 20 mL/min; Gradient: 30 B to 30 B in 12 min; 254/220 nm; RT1:6.2; RT2:8.4]. gave tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate (95 mg, 43.2 %, fraction 1) as a colourless oil and tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate (95 mg, 43.2 %, fraction 2) as a colourless oil. LCMS for both isomers: m/z (ESI), [M+H]<sup>+</sup> = 455.

- 15 *Step 2. 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]triazole-4-carbonitrile* **Compound 5**



- TFA (1 mL, 12.98 mmol) was added to tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate fraction 1 (60 mg, 0.13 mmol) in DCM (5 mL). The resulting mixture was stirred at 25 °C for 2 h and solvent was then removed under reduced pressure.
- 20 Purification by preparative HPLC Column: XBridge Shield RP18 OBD Column, 5µm, 19\*150mm; Mobile Phase A: Waters (0.05% aq. NH<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 20% B to 47% B in 7 min; 254/220 nm gave **Compound 5**, isomer 1 (73.0 mg, 56.4 %) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.58 - 1.71 (m, 1H), 1.75 (s, 1H), 1.97 (s, 3H), 2.50 (s, 3H), 2.74 (br s, 2H), 2.95 (m, 1H), 3.22 (m, 1H), 3.46 (m, 1H), 3.61 - 3.72 (m, 1H), 3.92 (br.s, 1H), 5.53 (s, 1H), 7.01 - 7.15 (m, 2H),
- 25 7.31 - 7.42 (m, 2H), 8.34 (dd, 1H). <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD) δ -77.222 (m, 16F), -118.395 (s, 1F), LCMS: m/z (ESI), [M+H]<sup>+</sup> = 355.

### Compound 6

*Step 1. Synthesis of tert-butyl (3R,5R)-1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)-5-fluoropiperidin-3-ylcarbamate*


- 30 Mitsunobu reaction of DIAD (235 mg, 1.16 mmol), PPh<sub>3</sub> (305 mg, 1.16 mmol), 1H-pyrazole-4-carbonitrile (64.9 mg, 0.70 mmol) and **F2b** (220 mg, 0.58 mmol) in DCM (20 mL) was performed at rt.

5 The crude product from work-up was purified by C18 flash column chromatography, elution gradient 0 to 48% MeCN in water (contains 0.3%  $\text{NH}_4\text{HCO}_3$ ). Pure fractions were evaporated to dryness to afford a pale yellow solid (220 mg, 80 %). LCMS: m/z (ESI),  $[\text{M}+\text{H}]^+ = 472$ . The crude product was further purified by preparative chiral-HPLC [Chiralpak IA column, eluting isocratically with 30% EtOH in Hexanes (modified with 0.1%DEA) as eluent to give tert-butyl (3R,5R)-1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)-5-fluoropiperidin-3-ylcarbamate isomer 1 (100 mg, 45.5 %, 100% ee)

10 as a pale yellow solid and tert-butyl (3R,5R)-1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)-5-fluoropiperidin-3-ylcarbamate isomer 2 (98 mg, 44.5 %, isomer 2, 100% ee) as a white solid. LCMS for both isomers: m/z (ESI),  $[\text{M}+\text{H}]^+ = 472$ .

Step 2. 1-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile

15 **Compound 6**



Boc-deprotection of tert-butyl (3R, 5R)-1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)-5-fluoropiperidin-3-ylcarbamate isomer 1 (100 mg, 0.21 mmol) was carried out with TFA (3 mL, 38.94 mmol) in DCM (20 mL) at 0°C. After standard work-up, the crude product was purified by preparative

20 HPLC [(XBridge Prep C18 OBD column, 5 $\mu\text{m}$  silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.05% TFA) and MeCN as eluents]. Fractions containing the desired compound were evaporated to dryness to afford **Compound 6**, isomer 1 as the TFA salt (68.0 mg, 37.1 %) as a white solid. LCMS: m/z (ESI),  $[\text{M}+\text{H}]^+ = 372$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ) 8.52 - 8.44 (1 H, d), 8.03 - 7.96 (1 H, s), 7.41 - 7.29 (2 H, m), 7.13 - 7.00 (2 H, m), 5.06 - 4.95 (1.5 H, m), 4.81 (0.5H, s) 3.79 - 3.64 (1 H, dt), 3.66 - 3.49 (2 H, m), 3.14 - 3.03 (1 H, d), 3.03 - 2.89 (1 H, q), 2.79 - 2.60 (1 H, dd), 2.49 - 2.29 (4 H, ddd), 2.26 - 2.15 (1 H, d), 1.97 - 1.74 (2 H, m).  $^{19}\text{F}$  NMR (282 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  -77.36, -118.84, -185.37.

25

**Compound 7**

Step 1. tert-butyl 1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)-4,4-difluoropiperidin-3-yl carbamate


30

- 5 Mitsunobu reaction of di-tert-butyl (E)-diazene-1,2-dicarboxylate (220 mg, 0.21 mmol) **F2c** (220 mg, 0.53 mmol), 1H-pyrazole-4-carbonitrile (10 mg, 0.11 mmol) and PPh<sub>3</sub> (56.4 mg, 0.21 mmol) in DCM (10 mL) at 5°C under nitrogen, gave after standard work-up and flash alumina chromatography (elution gradient 0 to 60% MeCN in water) tert-butyl 1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)-4,4-difluoropiperidin-3-ylcarbamate (120 mg, 46 %) as a colourless oil. The
- 10 crude product was further purified by preparative chiral-HPLC [ (Column: Phenomenex Lux 5u Cellulose-4, AXIA Packed, 2.12\*25cm, 5µm; Mobile Phase A: Hexanes-HPLC, Mobile Phase B: EtOH-HPLC; Flow rate: 20 mL/min; Gradient: A:B = 80:20 in 40 min; 254/220 nm; RT1:10.664 ; RT2:13.923)] to afford 3 isomers (all white solid and m/z (ESI), [M+H]<sup>+</sup> = 490.4): isomer 1 (50.0 mg, 41.7 %, 98% ee), isomer 2 (40.0 mg, 33.3 %, 98% ee) and isomer 3 (30.0 mg, 25.00 %, 100% ee; LCMS for all isomers:
- 15 m/z (ESI), [M+H]<sup>+</sup> = 490.

EA

Step 2. 1-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile

**Compound 7**




- 20 Boc deprotection of tert-butyl 1-(2-(4-cyano-1H-pyrazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)-4,4-difluoropiperidin-3-ylcarbamate isomer 2 (40 mg, 0.08 mmol) in DCM (3 mL) at 25°C with TFA (47.5 mg, 0.49 mmol) gave, after preparative HPLC (Column: XBridge Prep C18 OBD Column 19×150mm 5µm; Mobile Phase A: Water(10mmol/L NH<sub>4</sub>HCO<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 46% B to 47% B in 7 min; 254/220 nm; Rt: 6.05 min) **Compound 7** (15.00 mg, 47.1 %) as a
- 25 yellow solid. 1H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.70 - 2.03 (2 H, m), 2.05 - 2.24 (1 H, m), 2.25 - 2.45 (4 H, m), 2.61 (2 H, dddd), 2.80 - 3.11 (2 H, m), 3.45 - 3.87 (2 H, m), 4.94 - 5.03 (1 H, m), 6.97 - 7.16 (2 H, m), 7.26 - 7.45 (2 H, m), 7.97 (1 H, s), 8.46 (1 H, s). 19F NMR (282 MHz, CD<sub>3</sub>OD) δ -119.11 - -118.71 (m), -107.36, -106.52. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 390.

**Compound 8**

- 30 Step 1. tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-(1H-pyrazol-1-yl)cyclopentyl)piperidin-3-ylcarbamate

5 Mitsunobu reaction of **F2a** (10 g, 26.42 mmol), 1H-pyrazole (18 g, 264.40 mmol), PPh<sub>3</sub> (14 g, 53.38 mmol) and DTAD (12 g, 52.11 mmol) in DCM (1.5L) was performed at 0°C under nitrogen. After standard work up C18 flash column chromatography, (0 to 100% MeCN in water) gave the crude product (9.80 g, 87 %) as a yellow oil. LCMS : m/z (ESI), [M+H]<sup>+</sup> = 429; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.47 (9 H, d), 1.52 - 1.82 (6 H, m), 2.20 - 2.55 (6 H, m), 2.66 (1 H, d), 3.53 - 3.81 (2 H, m), 4.75 (2 H, s), 6.27 (1 H, dt), 7.01 (2 H, t), 7.23 (2 H, td), 7.48 - 7.59 (2 H, m). The crude product (4.5g) was purified by on a Waters SFC 350 Preparative System [Phenomenex Lux 5u Cellulose-3, 5cm x 25cm, 5µm; Mobile Phase A: CO<sub>2</sub> :80%, Mobile Phase B: MeOH (0.1% isopropylamine):20%; Flow rate: 160 mL/min; 220 nm; RT1:3.93; RT2:4.58] to afford tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-(1H-pyrazol-1-yl)cyclopentyl)piperidin-3-ylcarbamate (2.000 g, 44.4 %, 98.7% ee, isomer 1) as a yellow solid.

15 *Step 2. 1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine **Compound 8***



Boc-deprotection of tert-butyl ((R)-1-((1S,2S,4R)-4-(4-fluorophenyl)-2-(1H-pyrazol-1-yl)cyclopentyl)piperidin-3-yl) carbamate isomer 1 (2.0 g, 4.667 mmol) in DCM (30.0 mL) with TFA (6.0 mL) was performed as described above. Flash silica chromatography (0 to 10% MeOH in DCM, 2% Ammonium hydroxide in DCM was used to basify the silica column) gave **Compound 8** (1.400 g, 91 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 329; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.10 (1 H, dtd), 1.48 - 2.08 (6 H, m), 2.13 - 2.49 (3 H, m), 2.77 (2 H, ddt), 2.89 - 3.02 (1 H, m), 3.54 (2 H, ddt), 4.91 (1 H, td), 6.31 (1 H, t), 7.03 (2 H, ddt), 7.28 - 7.39 (2 H, m), 7.53 (1 H, d), 7.79 (1 H, dd). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ -119.16.


### Compound 9

25 *Step 1. tert-butyl (3R, 5R)- 5-fluoro- 1-(4-(4-fluorophenyl)- 2-(1H-pyrazol-1-yl) cyclopentyl) piperidin-3-yl carbamate*

DTAD (1.742 g, 7.57 mmol) was added to **F2b** (1.0 g, 2.52 mmol), 1H-pyrazole (0.859 g, 12.61 mmol) and PPh<sub>3</sub> (1.985 g, 7.57 mmol) in DCM (50 mL) cooled to 0°C over a period of 5 minutes under nitrogen. The resulting mixture was stirred at rt for 3 hours. The crude product was purified by preparative HPLC [XBridge Prep OBD C18 Column 19\*250mm, 5µm; Mobile Phase A: Water (0.05% aq. NH<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 60 mL/min; Gradient: 40% B to 50% B in 7 min; 220,254 nm; RT: 6.48 min]

5 to afford tert-butyl (3R,5R)-5-fluoro-1-(4-(4-fluorophenyl)-2-(1H-pyrazol-1-yl)cyclopentyl)piperidin-3-yl carbamate (0,700 g, 62.2 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 447.3; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.58 (d, 1H), 7.51 (t, 1H), 7.24 (ddd, 2H), 7.11 - 6.94 (m, 2H), 6.29 (q, 1H), 4.73 (d, 2H), 3.68 - 3.46 (m, 3H), 2.83 (s, 1H), 2.74 - 2.52 (m, 2H), 2.39 (t, 3H), 2.34 - 2.19 (m, 1H), 2.00 (s, 1H), 1.78 (dt, 2H), 1.63 (s, 1H), 1.48 (d, 9H). Preparative SFC on a Waters SFC 350 Preparative System [Chiralpak AS-H, 5\*25cm, 10 5μm; Mobile Phase A: CO<sub>2</sub> :70%, Mobile Phase B: MeOH-Preparative: 30%; Flow rate: 150 mL/min; 220 nm; RT1:4.2; RT2:5.31] delivered the desired product as isomer 1 (330 mg, 47,1 %) a white solid and isomer 2 (335 mg, 47.9 %) a yellow gum.


*Step 2. 5-fluoro-1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine **Compound 9***



15 TFA (2.0 mL) was added to tert-butyl ((3R,5S)-5-fluoro-1-((1S,2S,4R)-4-(4-fluorophenyl)-2-(1H-pyrazol-1-yl)cyclopentyl)piperidin-3-yl)carbamate isomer1 (328 mg, 0.73 mmol) in DCM (8 mL). The resulting mixture was stirred at rt for 2 hours. Preparative HPLC [XBridge Prep OBD C18 Column 30×150mm, 5μm; Mobile Phase A: Water (0.05%NH<sub>3</sub>H<sub>2</sub>O), Mobile Phase B: MeCN; Flow rate: 60 mL/min; Gradient: 25% B to 50% B in 7 min; 254/220 nm; Rt: 5.40 min] gave **Compound 9** (120 mg, 47.2 %, isomer 1) as 20 a white solid. m/z (ESI), [M+H]<sup>+</sup> = 347.1; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.81 (d, 1H), 7.54 (d, 1H), 7.43 - 7.25 (m, 2H), 7.12 - 6.97 (m, 2H), 6.32 (t, 1H), 5.01 - 4.88 (m, 1H), 4.75 - 4.64 (m, 1H), 3.67 - 3.45 (m, 2H), 3.17 - 2.83 (m, 3H), 2.49 - 2.15 (m, 4H), 2.14 - 1.74 (m, 3H), 1.43 (dddd, 1H). <sup>19</sup>F NMR (282 MHz, CD<sub>3</sub>OD) δ -119.15, -183.33.


**Compound 10**

25 *Step 1. tert-butyl N-[(3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]-3-piperidyl]carbamate and tert-butyl N-[(3R,5R)-5-fluoro-1-[(1S,2S,4R)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]-3-piperidyl]carbamate*



A 0 °C solution of 1:1 mixture of tert-butyl N-[(3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-hydroxy-cyclopentyl]-3-piperidyl]carbamate and tert-butyl N-[(3R,5R)-5-fluoro-1-[(1S,2S,4R)-4-(4-fluorophenyl)-2-hydroxy-cyclopentyl]-3-piperidyl]carbamate (**F2b**) (12 g, 30.27 mmol), 1H-1,2,4-triazole (3.14 g, 45.40 mmol) and PPh<sub>3</sub> (11.91 g, 45.40 mmol) in THF (150 mL) was treated with diisopropyl azodicarboxylate (9.18 g, 45.40 mmol). After 3h at 25 °C, the solvent was removed under reduced pressure. C18 flash column chromatography of the residue (10 to 28% MeCN in water (with 0.2% TFA)) to give the desired Mitsunobu products (12.00 g, 89 %) as a light-yellow oil.

10



A mixture of the diastereomers from a series of reactions described above (i.e. tert-butyl N-[(3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]-3-piperidyl]carbamate and tert-butyl N-[(3R,5R)-5-fluoro-1-[(1S,2S,4R)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]-3-piperidyl]carbamate) (694 g, 1.55 mol) was separated by Chiral-SFC [Column: CelluCoat, 50 x 250 mm, 10 μm; Mobile Phase: 17% MeOH in CO<sub>2</sub>; Flow rate: 450 mL/min; 260 nm; RT1:2.25 min; RT2:2.88 min] to give tert-butyl N-[(3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]-3-piperidyl]carbamate (isomer 1) (335.3 g, 48.3 %, 99.8% ee/de) as a white solid. 1H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.44 (9 H, s), 1.73 - 1.93 (3 H, m), 2.17 - 2.44 (4 H, m), 2.55 (1 H, s), 2.62 - 2.9 (2 H, m), 3.54 (2 H, dt), 3.94 (1 H, s), 4.79 (3 H, ddd), 6.9 - 7.07 (2 H, m), 7.20 (2 H, ddd), 7.97 (1 H, s), 8.19 (1 H, s); LCMS: m/z (ES+), [M+H]<sup>+</sup> = 448; and tert-butyl N-[(3R,5R)-5-fluoro-1-[(1S,2S,4R)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]-3-piperidyl]carbamate (isomer 2) (343 g, 49.4 %, 98.1% ee/de) as a white solid. 1H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.45 (9 H, s), 1.74 (3 H, q), 2.18 - 2.46 (4 H, m),


15

20

25

- 5 2.56 - 2.82 (3 H, m), 3.53 (2 H, dtd), 3.97 (1 H, s), 4.80 (3 H, ddd), 6.93 - 7.06 (2 H, m), 7.20 (2 H, ddd), 7.97 (1 H, s), 8.16 (1 H, s); LCMS: m/z (ES+), [M+H]<sup>+</sup> = 448.

Step 2. (3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine **Compound 10**



- 10 Boc-deprotection of *tert*-butyl N-[(3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]-3-piperidyl]carbamate isomer 1 (335 g, 0.75 mol) in isopropanol (1.32 L) was carried out under a nitrogen atmosphere, by adding 3.8 M HCl (aq. 1.18 L, 4.5 mol, 6 eq.) at 20 °C, then stirring for 15 h at 50 °C. The solvents were removed by vacuum and the residue was diluted with DCM (2.5 L), cooled to *ca* 10 °C and basified to pH 10-11 with 1.5 M Na<sub>2</sub>CO<sub>3</sub> (*ca* 2.5 L needed). The organic layer was separated and the aqueous layer was back-extracted with DCM (1.5 L). The combined organic layers were washed with water (1 L) and dried over Na<sub>2</sub>SO<sub>4</sub>. After polish filtration and evaporation of the solvents 260 g of the (3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine was obtained as a white amorphous solid (quantitative yield).


- Crystallisation to the desired polymorph, referred to above as Compound **10** Form A or Form A, was performed by adding isopropyl acetate (450 mL) to (3R,5R)-5-fluoro-1-[(1R,2R,4S)-4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine (280 g, 804 mmol) and heating at 70 °C during 30 minutes (until a homogeneous solution was produced). Heptane (450 mL) was then added in a portion-wise manner during 20-30 minutes. After stirring for 30 minutes at 70 °C the temperature was decreased stepwise and stirring continued at *ca* 20 °C overnight (*ca* 16 h). For XRPD analysis, the resultant solid Form A was isolated by filtration and then washed with cold heptane (150 - 200 mL). Drying overnight at 40 °C *in vacuo* yielded 269 g (96.4 % yield, >99.9 % ee/de) of Compound 10 Form A as a white crystalline solid. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 1.31 (1 H, m), 1.71 (1 H, q), 1.85 (2 H, m), 1.91 (1H, d), 2.20 (2 H, d), 2.24 (2 H, m), 2.33 (1 H, dd), 2.81 (1 H, d), 2.84 (1H, s), 2.89 (1 H, s), 3.38 (1 H, m), 3.49 (1 H, m), 4.78 (1 H, d), 5.01 (1 H, s), 7.12 (2 H, t), 7.37 (2 H, dd), 8.01 (1 H, s), 8.67 (1 H, s); LCMS: m/z (ES+), [M+H]<sup>+</sup> = 348. For crystallography data see above at e.g. Table 1 and Figure 1.

### Compound 11

5 *Step 1. tert-butyl (3R,5R)-5-fluoro-1-(4-(4-fluorophenyl)-2-(2H-tetrazol-2-yl) cyclopentyl) piperidin-3-yl carbamate*

Di-tert-butyl azodicarboxylate (437 mg, 1.90 mmol) was added to **F2b** (376 mg, 0.95 mmol), 2H-tetrazole (100 mg, 1.42 mmol) and Ph<sub>3</sub>P (497 mg, 1.90 mmol) in DCM (30 mL) at 0°C under nitrogen. The resulting mixture was stirred at 25 °C for 8 hours and then the solvent was removed under reduced pressure. The crude product was purified by flash C18-flash chromatography (0 to 40% MeCN in water). Pure fractions were evaporated to dryness to afford trans tert-butyl (3R, 5R)-5-fluoro-1-(4-(4-fluorophenyl)-2-(2H-tetrazol-2-yl)cyclopentyl)piperidin-3-ylcarbamate (253 mg, 59.5 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 449.5. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.78 (s, 1H), 7.38 (dd, 2H), 7.06 (t, 2H), 5.68 - 5.55 (m, 1H), 4.74 (s, 1H), 3.85 (s, 1H), 3.73 - 3.57 (m, 2H), 3.10 - 2.92 (m, 2H), 2.51 - 2.35 (m, 4H), 2.12 - 1.86 (m, 4H), 1.45 (d, 9H). The crude product was purified by preparative chiral-HPLC on a Chiralpak IA column, eluting isocratically with 20% EtOH in Hexanes (0.1% DEA) as eluent. The fractions containing the desired compound were evaporated to dryness to afford, isomer 1 (114 mg, 45.1 %, isomer 1, 100% ee) and fraction 2 (18.00 mg, 7.11 %, mixture (isomer 2 and isomer 3) and isomer 4 (89 mg, 35.2 %, 95.5% ee) as a white solid.

20 *Step 2. 5-fluoro-1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine **Compound 11***




TFA (1 mL, 12.98 mmol) was added to isomer 1 of the foregoing (112 mg, 0.25 mmol) in DCM (4 mL) at 25°C to remove the Boc group. The resulting mixture was stirred at 25 °C for 2 hours and then the solvent was removed under reduced pressure. The crude product was purified by preparative HPLC [(XBridge Prep C18 OBD column, 5µm silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.05% NH<sub>3</sub>H<sub>2</sub>O) and MeCN as eluents]. Fractions containing the desired compound were evaporated to dryness to afford **Compound 11** (40.0 mg, 46.0 %, isomer 1) as a white solid. This proved to be the most potent isomer. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 349.5. DSC: temp: 272.86°C; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.79 (s, 1H), 7.52 - 7.31 (m, 2H), 7.18 - 6.98 (m, 2H), 5.59 (ddd, 1H), 4.75 (s, 1H), 3.66 (ddt, 2H), 3.20 - 2.94 (m, 3H), 2.59 - 2.26 (m, 4H), 2.28 - 1.86 (m, 3H), 1.62 - 1.23 (m, 1H). <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD) δ -118.88-118.76 (1F, s), 184.37-183.48 (1F, s).

5 **Compound 12**

*Step 1. tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-(2H-tetrazol-2-yl)cyclopentyl)piperidin-3-yl carbamate*

Di-tert-butyl (E)-diazene-1,2-dicarboxylate (122 mg, 0.53 mmol) was added to **F2a** (200 mg, 0.53 mmol), 2H-tetrazole (37.0 mg, 0.53 mmol) and triphenylphosphine (139 mg, 0.53 mmol) in DCM (10 mL) at 0°C over a period of 5 minutes under nitrogen. The resulting mixture was stirred at rt for 15 hours. The solvent was removed under reduced pressure. Alumina flash column chromatography (0 to 70% MeCN in water) gave a white solid (155 mg, 68 %) (LCMS: m/z (ESI), [M+H]<sup>+</sup> = 431.15; TFA, HPLC Rt = 0.729 min). Preparative chiral-HPLC [(Column: CHIRAL ART Cellulose-SB, 2x25cm, 5µm; Mobile Phase A: Hexanes (0.1%TFA), Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: A:B = 85:15 in 15 min; 254/220 nm; RT1:11.2 ; RT2:13.32] gave tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-(2H-tetrazol-2-yl)cyclopentyl)piperidin-3-ylcarbamate isomer 1 (70.0 mg, 45.1 %, 100% ee) as a colourless oil and isomer 2 (70.0 mg, 45.1 %, 100% ee) as a colourless oil.

*Step 2. 1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine **Compound 12***



TFA (96 mg, 0.98 mmol) was added to tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-(2H-tetrazol-2-yl)cyclopentyl)piperidin-3-ylcarbamate isomer 1 (70 mg, 0.16 mmol) in DCM (5 mL) at rt. After stirring for 1 hour at rt, the solvent was removed under reduced pressure. The crude product was purified by preparative HPLC [(Column: XBridge Prep OBD C18 Column 19x250mm, 5µm; Mobile Phase A: Water (0.05% aq. NH<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 36% B to 46% B in 7 min; 220,254 nm; Rt: 5.79 min to give **Compound 12** (25.00 mg, 46.5 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 331.5; TFA, HPLC Rt = 1.129 min; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.17 (1 H, dtd), 1.50 - 1.64 (1 H, m), 1.73 (1 H, ddd), 1.83 - 2.19 (4 H, m), 2.34 - 2.56 (3 H, m), 2.77 - 3.02 (3 H, m), 3.50 - 3.80 (2 H, m), 5.59 (1 H, ddd), 7.00 - 7.13 (2 H, m), 7.31 - 7.43 (2 H, m), 8.77 (1 H, s). <sup>19</sup>F NMR (282 MHz, CD<sub>3</sub>OD) δ -118.65, -76.86. DSC: temp:281.89°C.


**Compound 13**

30 *Step 1. tert-butyl (3R)-1-(2-(3-cyano-1H-1,2,4-triazol-1-yl)-4-(4-fluorophenyl)cyclopentyl) piperidin-3-yl carbamate*

5 Di-tert-butyl azodicarboxylate (426 mg, 1.85 mmol) was added to **F2a** (350mg, 0.92 mmol), 1H-1,2,4-triazole-3-carbonitrile (104 mg, 1.11 mmol) and Ph<sub>3</sub>P (485 mg, 1.85 mmol) in DCM (10 mL) at 25°C under nitrogen then stirred at 25 °C for 3 hours. After standard work up C18 flash column chromatography, (0 to 40% MeCN in water (containing 0.3% NH<sub>3</sub>OH)) gave a white solid (350 mg). Preparative TLC (petroleum ether: EtOAc = 2: 1), afforded fraction 1 (110 mg, 26%) & fraction 2 (230 mg, 55 %) as white solids. Fraction 1 was further separated by preparative chiral-HPLC on a Chiralpak IA column, eluting isocratically with Hexane in EtOH as eluent to give isomer 1 tert-butyl (3R)-1-(2-(3-cyano-1H-1,2,4-triazol-1-yl)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate (31.0 mg, 28%, 100% ee) and isomer 2 (37.0 mg, 34 %, 100% ee) as a white solid.

Step 2. 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]-1,2,4-triazole-3-carbonitrile

### 15 **Compound 13**



TFA (1.0 mL) was added to isomer 1 (31 mg, 0.07 mmol) obtained in step 1 in DCM (5 mL) at 25°C. The resulting mixture was stirred at 25 °C for 2 h, concentrated and then purified by preparative HPLC (XBridge Prep C18 OBD column, 5μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.05% TFA) and MeCN as eluents to give **Compound 13** (24.3 mg, 46%), as a white solid; LCMS: m/z (ESI) [M+H]<sup>+</sup> = 355.5; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.27 (s, 1H), 7.35 (dd, 2H), 7.06 (t, 2H), 5.44 (q, 1H), 4.04 (dt, 1H), 3.72-3.37 (m, 3H), 3.03-2.87 (m, 1H), 2.82 - 2.67 (m, 2H), 2.50 (ddd, 3H), 2.13-1.87 (m, 3H), 1.85-1.48 (m, 2H).

### **Compound 14 and Compound 15**

25 *Step 1. tert-butyl (3R)-1-(4-(4-fluoro-3-methoxyphenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate*  
To a solution of **F4** (100 mg, 1.0 eq.) in 3 mL anhydrous ethanol was added (R)-tert-butyl piperidin-3-ylcarbamate (115 mg, 1.2 eq.) and sodium carbonate (101 mg, 2.0eq.) in a sealed vial. The suspension was irradiated in microwave at 130°C for 6h, then filtered and concentrated. Column chromatography on (silica gel 0 to 3% methanol in DCM) to give tert-butyl (3R)-1-(4-(4-fluoro-3-methoxyphenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate (140 mg, 71% yield) as a colourless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>)


5 400MHz)  $\delta$  6.99 (dd, 1H), 3.86 (dd, 1H), 6.75-6.71 (m, 1H), 4.92 (br. s, 1H), 4.27-4.21 (m, 1H), 3.89 (s, 3H), 3.75 (br. s, 1H), 3.10-3.06 (m, 2H), 2.88-2.75 (m, 2H), 2.53 (br. s, 2H), 2.41-2.35 (m, 2H), 2.15-2.05 (m, 1H), 1.90-1.66 (m, 6H), 1.40 (d, 9H).

*Step 2. tert-butyl (3R)-1-(2-(4-cyanophenoxy)-4-(4-fluoro-3-methoxyphenyl) cyclopentyl) piperidin-3-yl carbamate*

10 A solution of tert-butyl (3R)-1-(2-(4-cyanophenoxy)-4-(4-fluoro-3-methoxyphenyl) cyclopentyl) piperidin-3-yl carbamate (140 mg, 1.0eq.) in 3 mL anhydrous THF was stirred and treated with NaH (35 mg, 2.5eq.). After 0.5h, 4-fluorobenzonitrile (50 mg, 1.2eq.) was added to the reaction which was then stirred for 18h at rt, and then at 45°C for 18h. The reaction mixture was then poured into 5 mL saturated solution of NH<sub>4</sub>Cl, extracted with EtOAc (5 mL x 3), dried and purified by column chromatography on silica gel (DCM/MeOH = 20/1) to afford the desired 4-cyanophenoxy compound  
 15 (80 mg, 46% yield). Purification using Waters SFC 350 Preparative System [column: AS (250mm\*30mm\*5 $\mu$ m), condition: 25% IPA in aq. NH<sub>3</sub> 60mL/min] gave tert-butyl (3R)-1-(2-(4-cyanophenoxy)-4-(4-fluoro-3-methoxyphenyl) cyclopentyl) piperidin-3-ylcarbamate isomer 1 (30 mg, 37% yield) and isomer 2 (35 mg, 43% yield); Isomer 1 shows LCMS Rt =0.892min in 5-95AB\_1.5min chromatography, MS (ESI) m/z = 510.3 [M+H]<sup>+</sup>. 1H NMR (CDCl<sub>3</sub>, 400MHz)  $\delta$  7.84 (dd, 1H), 7.60 (dd, 2H)  
 20 7.16-7.11 (m, 1H), 6.99-6.96 (m, 1H), 6.84-6.82 (m, 1H), 6.77-6.73 (m, 1H), 4.79-4.77 (m, 2H), 3.88 (s, 3H), 3.73 (br. s, 1H), 3.25-3.19 (m, 2H), 2.69-2.63 (m, 2H), 2.47-2.19 (m, 4H), 2.04-1.95 (m, 1H), 1.88-1.82 (m, 2H), 1.68-1.64 (m, 3H), 1.43 (d, 9H). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 510.

*Step 3. 4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-hydroxy-phenyl)cyclopentoxy]benzonitrile*

25 **(Compound 14)** and *4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-methoxy-phenyl)cyclopentoxy]benzonitrile* **(Compound 15)**



To a solution of isomer 1 of the carbamate described above (30 mg) in DCM (2 mL) was added BBr<sub>3</sub> (0.5 mL) at -78°C. The mixture was stirred at -78°C for 1h. The mixture was poured into aq. NH<sub>4</sub>Cl (20  
 30 mL), adjusted pH = 10 by using aq NaHCO<sub>3</sub>, then extracted with DCM (2 x 20 mL). The organic layers were dried over sodium sulfate, concentrated and purified by prep-HPLC [(method: column: Durashell

5 C18 150\*25mm\*5 $\mu$ m, gradient: 43-73% B (A = water/0.05% ammonia, B = acetonitrile), flow rate: 25 mL/min]] to give **Compound 14** (1.3 mg, 5.6% yield) and **Compound 15** (1.0 mg, 4.1% yield).

**Compound 14:** LCMS: m/z (ESI), [M+H]<sup>+</sup> = 396. <sup>1</sup>H NMR (CD<sub>3</sub>OD 400MHz)  $\delta$  7.65 (d, 2H), 7.15 (d, 2H), 6.93 (dd, 1H), 6.82 (d, 1H), 6.70-6.64 (m, 1H), 5.00-4.98 (m, 1H), 3.26-3.18 (m, 2H), 3.05 -2.95 (m, 1H), 2.93-2.63 (m, 3H), 2.30-2.14 (m, 2H), 2.10-1.95 (m, 2H), 1.90-1.65 (m, 3H), 1.63-1.49 (m, 1H), 1.24-1.10 (m, 1H).


**Compound 15:** LCMS: m/z (ESI), [M+H]<sup>+</sup> = 410. <sup>1</sup>H NMR (CD<sub>3</sub>OD 400MHz)  $\delta$  7.66 (d, 2H), 7.15 (d, 2H), 7.00-6.96 (m, 2H), 6.83-6.75 (m, 1H), 4.72-4.65 (m, 1H), 3.84 (s, 3H), 3.42-3.35 (m, 1H), 3.30-3.23 (m, 1H), 3.05-2.95 (m, 1H), 2.90-2.65 (m, 3H), 2.35-2.15 (m, 2H), 2.14-1.95 (m, 2H), 1.91-1.68 (m, 3H), 1.62 -1.49 (m, 1H), 1.25-1.13 (m, 1H).

### 15 **Compound 16**

*Step 1. tert-butyl (3R)-1-(2-(2-chloro-4-cyanophenoxy)-4-(3-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate*

To a solution of **F3** (580 mg) in THF (8 mL) was added NaH (184 mg, 3.0 eq) at 0 °C in portions. After stirred at the same temperature for 30min, 3-chloro-4-fluorobenzonitrile (285 mg, 1.2 eq) dissolved in THF (2 mL) was added in portions. The reaction mixture was stirred at rt overnight, then quenched with aqueous NH<sub>4</sub>Cl (20 mL), diluted with water (50 mL), extracted with ethyl acetate (50 mL x 3), dried over Na<sub>2</sub>SO<sub>4</sub>. The combined organic layer was concentrated to give the desired ether (920 mg) as yellow oil. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 514.

*Step 2. 4-[2-(3-amino-1-piperidyl)-4-(3-fluorophenyl)cyclopentoxy]-3-chloro-benzonitrile **Compound 16***



A solution of the above Boc protected compound (920 mg) in HCl/dioxane (10 mL) was stirred at rt for 2h then concentrated to give a solid. The solid was washed with ethyl acetate (3 x 20 mL), then dried to give a residue (350 mg, 47%), which was separated by Waters SFC 350 Preparative System [column: AD (250 x 30mm, 5 $\mu$ m), condition: 30% ethanol/ammonia flow rate: 60 mL/min] to give isomer 1 **Compound 16** (95.7 mg) and a second, isomer 2, of the same compound (125.1 mg).

5 Isomer 1 (**Compound 16**): LCMS: m/z (ESI)  $[M+H]^+ = 414$ . Most potent isomer:  $^1H$  NMR ( $CD_3OD$  400MHz)  $\delta$  7.81-7.80 (1H, m), 7.68-7.65 (1H, m), 7.31-7.28 (2H, m), 7.15-6.94 (3H, m), 5.06-4.92 (1H, m), 3.40-3.25 (2H, m), 3.05-2.95 (1H, m), 2.92-2.72 (2H, m), 2.45-2.36 (1H, m), 2.32-2.00 (4H, m), 1.90-1.51 (4H, m), 1.24-1.19 (1H, m).

Isomer 2: LCMS: m/z (ESI),  $[M+H]^+ = 414$ .  $^1H$  NMR ( $CD_3OD$  400MHz)  $\delta$  7.83-7.82 (1H, m), 7.68-7.67 (1H, m), 7.32-7.27 (3H, m), 7.05-7.01 (2H, m), 5.05-4.97 (1H, m), 3.43-3.35 (2H, m), 3.10-2.95 (1H, m), 2.95-2.75 (2H, m), 2.47-2.39 (1H, m), 2.35-2.05 (4H, m), 1.95-1.56 (4H, m), 1.28-1.22 (1H, m).


### Compound 17

*Step 1. tert-butyl 1-(2-(4-cyanophenoxy)-4-(4-fluorophenyl)cyclopentyl)-4,4-difluoropiperidin-3-ylcarbamate*

15 To a solution of tert-butyl 4,4-difluoro-1-(4-(4-fluorophenyl)-2-hydroxycyclopentyl)piperidin-3-ylcarbamate **F2c** (250 mg, 1.0 eq.), 4-hydroxybenzonitrile (86 mg, 1.2 eq.) and  $Ph_3P$  (470 mg, 3.0 eq.) in anhydrous THF (10 mL) was added DIAD (485 mg, 4.0 eq.) at 0°C under nitrogen dropwise. The resulting mixture was stirred at 14-22°C for 20h. After standard work up, flash chromatography (petroleum ether/EA = 90/10 to 80/20) gave the mixture of isomeric products (220 mg, 71% yield) as  
 20 yellow thick oil. Separation by Waters SFC 350 Preparative System (column: OJ 250mm\*30mm\*5 $\mu$ m, condition: base-methanol, flow rate: 60 mL/min) gave pure isomer 1 (20 mg, peak1) and isomer 2 (15 mg, peak2) and a mixture of two isomers (50 mg, peak 3+4) which was further separated by Waters SFC 350 Preparative System (column: IC 250mm\*30mm \*10 $\mu$ m, condition: base-methanol, flow rate: 70 mL/min) to give isomer 3 (15 mg, peak1 in second separation) and isomer 4 (10 mg, peak2 in second  
 25 separation). All isomers were obtained as colourless oils. LCMS for isomer 1: m/z (ESI)  $[M+H]^+ = 516$ .

*Step 2. 4-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]benzonitrile*

### Compound 17



To a solution of the above isomer 1 (20 mg, 1.0 eq.) in anhydrous dichloromethane (5 mL) was added  
 30 TFA (1 mL). The resulting mixture was stirred at 16-23°C for 1h. The mixture was poured into saturated  $NaHCO_3$  solution (50 mL), extracted with DCM (30 mL x 3), dried over anhydrous sodium

5 sulfate, concentrated. The residue was purified by pre-HPLC (column: Durashell 150\*25mm\*5 $\mu$ m, gradient: 70%-95%B (A= 0.05% ammonia/water, B = methanol, flow rate: 25 mL/min) to give **Compound 17** (2.9 mg, 18% yield) as white solid after lyophilisation. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 416. 1H NMR (CD<sub>3</sub>OD 400MHz)  $\delta$  7.68 (d, 2H), 7.33-7.29 (dd, 2H), 7.12 (d, 2H), 7.03 (t, 2H), 4.90-4.85 (m, 1H), 3.35-3.32 (m, 1H), 3.30-3.28 (m, 1H), 3.15-3.05 (m, 1H), 2.98-2.87 (m, 1H), 2.82-2.71 (m, 1H), 2.66-  
10 2.55 (m, 1H), 2.52-2.32 (m, 2H), 2.27-2.08 (m, 3H), 2.07-1.92 (m, 1H), 1.81-1.75 (m, 1H).


### Compound 18

*Step 1. tert-butyl (3R)-1-(2-(4-cyanophenoxy)-4-(4-fluorophenyl)cyclopentyl)-5,5-difluoropiperidin-3-yl carbamate*

To a mixture of PPh<sub>3</sub> (569 mg, 3.0eq.) and 4-hydroxybenzotrile (129 mg, 1.5eq.) was added solution  
15 of **F2d** (290 mg, 1.0eq.) and DIAD (439 mg, 3.0eq.) in 3 mL anhydrous THF under nitrogen. The yellow solution was stirred at 17-27°C for 18h. The solution was concentrated and purified by column on silica gel (petroleum ether/EtOAc, 0 to 20% EA), washed with saturated solution of potassium carbonate (3x10 mL) and concentrated to afford tert-butyl (3R)-1-(2-(4-cyanophenoxy)-4-(4-fluorophenyl)cyclopentyl)-5,5-difluoropiperidin-3-ylcarbamate (328 mg, 88% yield) as a white solid.  
20 LCMS: m/z (ESI), [M+H]<sup>+</sup> = 516.

*Step 2. 4-[2-(5-amino-3,3-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]benzotrile*

### Compound 18



To a solution of the above Boc-protected compound (328 mg, 1.0 eq.) in 5 mL DCM was added 2 mL  
25 TFA. The solution was stirred at rt for 1h then concentrated. The residue was diluted with aq. HCl and extracted with petroleum ether/EtOAc (1:1) (20 mL x 3) to remove impurities. The aqueous layer was basified with sodium bicarbonate and extracted with dichloromethane (10 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated to afford a yellow solid (50 mg, yield 19%) which was separated by Berger MG-II SFC Preparative System [ChiralPak AD 250x30mm  
30 I.D., 5 $\mu$ m; Mobile phase: CO<sub>2</sub>/MeOH (0.1% aq. NH<sub>3</sub>) = 70/30 at 60 mL/min] to afford **Compound 18** (5.2 mg, 10%) as a white solid. A second isomer, data not reported here, was also isolated.


- 5 **Compound 18** showed: LCMS: m/z (ESI),  $[M+H]^+ = 416$ .  $^1H$  NMR ( $CD_3OD$  400MHz)  $\delta$  7.68 (d, 2H), 7.32 (dd, 2H), 7.15 (d, 2H), 7.04 (t, 2H), 4.89-4.84 (m, 1H), 3.38-3.36 (m, 1H), 3.18 (br. s, 1H), 2.96-2.92 (m, 2H), 2.79-2.73 (m, 1H), 2.39-2.15 (m, 6H), 1.84-1.78 (m, 2H).

### Compound 19

- 10 *Step 1. tert-butyl (3R)-1-(2-(4-cyano-3-fluorophenoxy)-4-(4-fluorophenyl)cyclopentyl) piperidin-3-yl carbamate*

To a solution of **F2a** (200 mg), 2-fluoro-4-hydroxybenzotrile (108 mg, 1.5 eq) and  $PPh_3$  (272 mg, 2.0 eq) in THF (4 mL) was added DIAD (180 mg, 2.0 eq) in THF (1 mL) at 0°C. The mixture was stirred at 25°C for 3 days. The mixture was diluted with water (20 mL), extracted with EA (2 x 20 mL). The organic layers were dried over sodium, concentrated and purified by chromatography column on silica gel (petroleum ether/EA = 5/1) to give the product (200 mg, 76% yield), which was separated by Waters SFC 350 Preparative System [column: AD (300mm\*50mm, 10 $\mu$ m), condition: 35% IPA + aq.  $NH_3$  80mL/min] to give isomer 1 (77 mg, 38% yield,  $R_t = 8.21$  min) and isomer 2 (76 mg, 38% yield,  $R_t = 9.64$  min). LCMS for both isomers, m/z (ESI),  $[M+Na]^+ = 520$ .

- 20 *Step 2. 4-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]-2-fluoro-benzotrile **Compound 19***




A solution of isomer 1 obtained directly above (77 mg) in DCM (2 mL) and TFA (1 mL) was stirred at 27°C for 30 min. The mixture was concentrated and purified by pre-HPLC (method: column: Waters Xbridge C18 150\*20mm\*5 $\mu$ m, gradient: 65-95% B (A = water/0.05% ammonia, B = methanol), flow rate: 25 mL/min) to give **Compound 19** (13.5 mg, 20% yield). LCMS: m/z (ESI),  $[M+H]^+ = 398$ .  $^1H$  NMR ( $CD_3OD$  400MHz)  $\delta$  7.65 (t, 1H), 7.32-7.25 (m, 2H), 7.07-6.98 (m, 3H), 6.94 (dd, 1H), 4.84-4.80 (m, 1H), 3.30-3.24 (m, 1H), 3.20-3.14 (m, 1H), 3.03-2.94 (m, 1H), 2.89-2.73 (m, 2H), 2.38-2.32 (m, 1H), 2.25-2.07 (m, 3H), 1.99 (t, 1H), 1.92-1.84 (m, 1H), 1.81-1.66 (m, 2H), 1.64-1.48 (m, 1H), 1.21-1.11 (m, 1H).

### Compound 20

- 30 *Step 1. tert-butyl (3R)-1-(2-(2-cyanophenoxy)-4-phenylcyclopentyl) piperidin-3-yl carbamate*

5 To a stirred solution of **F1** (400 mg) in DMF (3 mL) was added NaH (133 mg, 3.0 eq) in portions at 0°C, then after 30 min, 2-fluorobenzonitrile (148 mg, 1.1 eq) dissolved in DMF (2 mL) was introduced dropwise and the reaction was stirred at rt overnight. After standard work up the reaction was purified by chromatography column (petroleum ether/EtOAc 1:1) to give crude tert-butyl (3R)-1-(2-(2-cyanophenoxy)-4-phenylcyclopentyl)piperidin-3-ylcarbamate (210 mg, 41 % yield). LCMS: m/z (ESI) [M+H]<sup>+</sup> = 462.

Step 2. 2-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy]benzonitrile **Compound 20**



To a stirred solution of the product of the preceding experiment (210 mg) in dichloromethane (3 mL) was added HCl/dioxane (2 mL, 4M) at rt. Then the mixture was stirred at rt for 2h, then extracted with dichloromethane (15 mL x 3) and then the aqueous was adjusted to pH 8 by adding saturated solution of NaHCO<sub>3</sub>. The aqueous layer was extracted with dichloromethane (20 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to crude give 2-(2-((R)-3-aminopiperidin-1-yl)-4-phenylcyclopentyl)oxybenzonitrile (93 mg, 56 % yield). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 362. Purification using Waters SFC 350 Preparative System on this crude product [column: OJ (250 nm\*30nm\*5µm), condition: 30% ethanol/ammonia flow rate: 60 ml/min] gave **Compound 20** (23.2 mg, isomer 1) and a second, less potent, isomer (10.5 mg, isomer 2).

**Compound 20** (Isomer 1): LCMS: m/z (ESI), [M+H]<sup>+</sup> = 361. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400MHz) δ 7.64-7.60 (m, 2H), 7.30-7.28 (m, 4H), 7.20-7.18 (m, 2H), 7.10-7.06 (m, 1H), 3.38-3.35 (m, 1H), 3.35-3.33 (m, 1H), 2.86-2.81 (m, 3H), 2.40-1.60 (m, 9H), 1.22-1.16 (m, 1H). Isomer 2 LCMS: m/z (ESI), [M+H]<sup>+</sup> = 362. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400MHz) δ 7.64-7.60 (m, 2H), 7.30-7.28 (m, 4H), 7.21-7.17 (m, 2H), 7.10-7.07 (m, 1H), 3.37-3.34 (m, 1H), 3.25-3.23 (m, 1H), 3.01-2.81 (m, 3H), 2.41-1.63 (m, 9H), 1.21-1.13 (m, 1H).


**Compound 21**

1. tert-butyl (3R)-1-(2-(2-chloro-4-cyanophenoxy)-4-phenylcyclopentyl)piperidin-3-ylcarbamate

To a mixture of NaH (1.1 g, 2.5 eq.) in anhydrous THF (20 mL) was added a solution of **F1** (4.0 g, 1.0 eq., 11.1 mmol) in THF (30 mL) dropwise at 0°C under nitrogen. After stirring for 0.5h, a solution of 3-chloro-4-fluorobenzonitrile (2.0 g, 1.2 eq.) in THF (10 mL) was added to the reaction. After stirring at

- 5 17-21°C for another 18h the mixture was poured into water (200 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. Column chromatography on silica gel (0 to 30% ethyl acetate in petroleum ether) to afford tert-butyl (3R)-1-(2-(2-chloro-4-cyanophenoxy)-4-phenylcyclopentyl)piperidin-3-ylcarbamate isomer 1 (460 mg, 8.3% yield) and a mixture of other products. Isomer 1 was the least polar product observed from TLC.
- 10 <sup>1</sup>H NMR (CDCl<sub>3</sub> 400MHz) δ 1.45 (9H, s), 1.61-1.85 (4H, m), 2.05-2.46 (4H, m), 2.48 (2H, br. s), 2.73 (1H, br. s), 3.15-3.25 (1H, m), 3.34-3.42 (1H, m), 3.75 (1H, br. s), 4.75 (1H, br. s), 4.85 (1H, br. s), 7.08-7.15 (1H, m), 7.23-7.26 (3H, m), 7.29-7.32 (2H, m), 7.52-7.55 (1H, m), 7.66-7.67 (1H, m).

*Step 2. 4-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxy]-3-chloro-benzonitrile Compound 21*



- 15 To a solution of isomer 1 (610 mg, 1.0 eq., 1.23 mmol) obtained in the preceding experiment in dichloromethane (5 mL) was added TFA (3 mL). The resulting solution was stirred for 0.5h at 7-17°C. The solution was then concentrated, diluted with water (10 mL), basified with ammonia and extracted with DCM (15 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was diluted with water then dried (lyophilisation) to afford the final
- 20 product **Compound 21** (348.6 mg, 71% yield) as white solid. LCMS: Rt = 1.633 in 4.0 min chromatography, LCMS: m/z (ESI), [M+H]<sup>+</sup> = 396. <sup>1</sup>H NMR (CD<sub>3</sub>OD 400MHz) δ 1.13-1.26 (1H, m), 1.53-1.66 (1H, m), 1.70-1.77 (1H, m), 1.77-1.85 (1H, m), 1.86-1.94 (1H, m), 2.01-2.07 (1H, m), 2.09-2.17 (1H, m), 2.18-2.29 (2H, m), 2.36-2.45 (1H, m), 2.76-2.83 (1H, m), 2.84-2.92 (1H, m), 2.98-3.05 (1H, m), 3.22-3.39 (2H, m), 4.91-4.95 (1H, m), 7.16-7.22 (1H, m), 7.24-7.33 (5H, m), 7.66 (1H, dd), 7.80 (1H, d).

25 **Compound 22**

*Step 1. tert-butyl (3R,5R)- 1-(2-(6-chloro- 4-methylpyridazin- 3-yloxy)- 4-(4-fluorophenyl) cyclopentyl)- 5-fluoropiperidin-3-yl carbamate*


- F2b** (950 mg, 2.40 mmol) was added to NaH (115 mg, 4.79 mmol), 3,6-dichloro-4-methylpyridazine (586 mg, 3.59 mmol) in DMF (8mL) cooled to 0°C over a period of 5 minutes under nitrogen. The
- 30 resulting solution was stirred at rt. for 2 hours. The residue was purified by preparative TLC (petroleum ether: EtOAc = 2:1) to afford the product as yellow oil (450 mg, 35.9 %); LCMS: m/z (ESI), [M+H]<sup>+</sup> = 523; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 7.89 - 7.58 (m, 1H), 7.35 (t, 2H), 7.11 (td, 2H), 6.79 (dd, 1H), 5.48

5 (t, 1H), 4.85 (d, 1H), 3.67 (s, 1H), 3.34 (s, 2H), 3.17 (d, 1H), 2.51 (m, 4H), 2.36 - 2.08 (m, 4H), 2.13 - 1.79 (m, 2H), 1.76 - 1.47 (m, 2H), 1.43 - 1.26 (m, 21H).

*Step 2. tert-butyl (3R,5R)-1-(2-(6-cyano-4-methylpyridazin-3-yloxy)-4-(4-fluorophenyl)cyclopentyl)-5-fluoropiperidin-3-ylcarbamate*

The 6-chloro-4-methylpyridazin-3-yloxy compound (150 mg, 0.29 mmol) obtained above was added  
 10 to zinc cyanide (67.3 mg, 0.57 mmol) and 2-di-t-butylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl (18.27 mg, 0.04 mmol) in THF (5mL) under nitrogen. The resulting mixture was stirred at 80 °C for 1 hour then evaporated. The residue was purified by preparative TLC (petroleum ether: EtOAc = 2: 1), to afford crude product (120 mg, 81 %) as a yellow oil. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 514; basic, HPLC Rt = 1.371 min. Preparative chiral-HPLC [CHIRALPAK IE, 2cm x 25cm, 5µm; Mobile Phase A:Hexanes (0.1%  
 15 DE) -HPLC, Mobile Phase B: EtOH-HPLC; Flow rate: 20 mL/min; Gradient: A:B = 70:30 in 31 min; 220/254 nm] afforded 8 fractions each with an ee of >98%; Fraction 1 (RT1: 9.37 minutes , 10.00 mg, 6.67 %) as a white solid. Isomer 2 (RT2: 12.16 minutes; 15.00 mg, 10.00 %) as a white solid. Isomer 3 (RT3: 14.92 minutes; 10.00 mg, 6.67 %) as a white solid. Isomer 4 (RT4:17.38 minutes; 10.00 mg, 6.67 %) as a white solid. Isomer 5 (RT5: 18.6 minutes; 5.00 mg, 3.33 %) as a white solid. Isomer 6 (RT6: 21.8  
 20 minutes; 20.00 mg, 13.33 %) as a white solid. Isomer 7 (RT7: 23.6 minutes; 15.00 mg, 10.00 %) as a white solid. Isomer 8 (RT8: 28 minutes; 10.00 mg, 6.67 %) as a white solid.

*Step 3. 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]-5-methyl-pyridazine-3-carbonitrile **Compound 22***



25 TFA (0.1 mL, 0.02 mmol) was added to isomer 4 obtained above (8 mg, 0.02 mmol) in DCM (1 mL). The resulting solution was stirred at rt for 30 minutes. The solvent was removed under reduced pressure. The mixture was adjusted to pH=8 with aq. NH<sub>3</sub>. The crude product was purified by preparative HPLC [(XBridge Prep OBD C18 Column 30×150mm 5µm; Mobile Phase A: Water (0.05% aq. NH<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 55 mL/min; Gradient: 35% B to 55% B in 7 min; 254/220 nm; Rt: 6.15 mins)].  
 30 Fractions containing the desired compound were evaporated to dryness to afford **Compound 22** (4.40

5 mg, 68.3 %) as a white solid, which proved the potent isomer. LCMS:  $m/z$  (ESI),  $[M+H]^+ = 414$ ;  $^1H$  NMR (300 MHz,  $CD_3OD$ )  $\delta$  7.89 (s, 1H), 7.30 - 7.30 (m, 2H), 7.07 - 7.0 (m, 2H), 5.82 (br s, 1H), 5.02 (br s, 1H), 3.58 (br s, 2H), 3.34 (m, 1H), 3.18 (m, 2H), 2.90 (m, 2H), 2.47 (m, 1H), 2.38 - 2.13 (m, 6H), 1.85 (m, 2H).  $^{19}F$  NMR (282 MHz,  $CD_3OD$ )  $\delta$  -118.834, -185.169.

### Compound 23


10 *Step 1.* ((3*R*)-1-(2-((4-chloropyridazin-3-yl)oxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl) carbamate

**F2** (500 mg, 1.32 mmol) was added to  $PPh_3$  (520 mg, 1.98 mmol) and 4-chloropyridazin-3(2*H*)-one (207 mg, 1.59 mmol) in DCM (8mL) at 0°C over a period of 5 minutes under nitrogen. DEAD (0.314 mL, 1.98 mmol) was then introduced in a dropwise manner. The resulting solution was allowed to warm to rt and stirred over 2 hours. The solvent was then removed under reduced pressure and the residue was purified by silica gel flash column chromatography with elution gradient 0 to 50% EtOAc in petroleum ether to afford yellow oil (1000.0 mg, 154 %). The crude product was purified by Waters SFC 350 Preparative System [(Column: (R,R)WHELK-01 5/100 Kromasil, 2.11cm\*25cm (5 $\mu$ m); Mobile Phase A:  $CO_2$ : 65%, Mobile Phase B: EtOH-HPLC: 35%; Flow rate: 45 mL/min; 220 nm ; RT1:4.06 ; RT2:4.85)] to afford tert-butyl ((3*R*)-1-(2-((4-chloropyridazin-3-yl)oxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl)carbamate isomer 1 (220 mg, 36.7 %, 100% ee) as a yellow solid and isomer 2 (240 mg, 40.0 %, 96.1% ee) as a yellow solid.

Isomer 1 LCMS:  $m/z$  (ESI),  $[M+H]^+ = 491$ ;  $^1H$  NMR (400 MHz,  $DMSO-d_6$ )  $\delta$  8.03 (d, 1H), 7.79 (d, 1H), 7.40 - 7.31 (m, 2H), 7.17 - 7.07 (m, 2H), 6.59 (d, 1H), 3.47 (dq, 1H), 3.33 (s, 3H), 3.17 (d, 1H), 2.75 (d, 1H), 2.62 (s, 1H), 2.25 - 2.14 (m, 2H), 2.03 (d, 2H), 1.94 (d, 2H), 1.82 - 1.71 (m, 1H), 1.62 (s, 1H), 1.53 (s, 1H), 1.37 (s, 9H).

Isomer 2 LCMS:  $m/z$  (ESI),  $[M+H]^+ = 491$ ;  $^1H$  NMR (400 MHz,  $DMSO-d_6$ )  $\delta$  8.04 (d, 1H), 7.80 (d, 1H), 7.40 - 7.32 (m, 1H), 7.11 (t, 2H), 6.60 (d, 1H), 3.44 (d3H), 3.17 (m, 1H), 2.52 (s, 5H), 2.36 - 2.14 (m, 2H), 2.00 (s, 1H), 1.89 (s, 1H), 1.84 - 1.70 (m, 2H), 1.67 (d, 1H), 1.55 (s, 1H), 1.36 (s, 9H).

30 *Step 2.* 1-[2-(4-chloropyridazin-3-yl)oxy-4-(4-fluorophenyl)cyclopentyl]piperidin-3-amine **Compound 23**



5

To a solution of isomer 2 (240 mg, 0.49 mmol) in DCM (10 mL) was added TFA (1 mL, 0.49 mmol). The resulting solution was stirred at rt for 30 minutes and then the solvent was evaporated. The mixture was adjusted to pH=8 with  $\text{NH}_3 \cdot \text{H}_2\text{O}$ . Preparative HPLC [(XBridge Prep OBD C18 Column 30x150mm 5 $\mu\text{m}$ ; Mobile Phase A: Water (0.05% aq.  $\text{NH}_3$ ), Mobile Phase B: MeCN; Flow rate: 55 mL/min; Gradient: 35% B to 40% B in 7 min; 254/220 nm; Rt: 5.53 min) gave **Compound 23** (128 mg, 67.0 %) as a white solid, which proved the more potent isomer. LCMS: m/z (ESI),  $[\text{M}+\text{H}]^+ = 391$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  8.00 (d, 1H), 7.66 (d, 1H), 7.38 - 7.24 (m, 2H), 7.10 - 6.95 (m, 2H), 5.71 (ddd, 1H), 3.56 (dt, 2H), 2.98 (d, 1H), 2.81 (t, 2H), 2.47 - 2.00 (m, 4H), 1.94 - 1.34 (m, 5H), 1.11 (d, 1H).  $^{19}\text{F}$  NMR (282 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  -119.158.


#### 15 **Compound 24**

*Step 1. tert-butyl (3R,5R)-1-(2-(6-cyanopyridazin-3-yloxy)-4-(4-fluorophenyl)cyclopentyl)-5-fluoropiperidin-3-ylcarbamate*

A solution of **F2b** (26 g, 65.58 mmol) in THF (300 mL) was cooled to 0°C then treated with sodium hydride (4.72 g, 196.73 mmol), and after 10 mins, 6-chloropyridazine-3-carbonitrile (10.98 g, 78.69 mmol). The resulting mixture was stirred at 0°C for 30 minutes, and rt for 30 minutes. After standard work up, the crude product was purified by flash C18-flash chromatography (0 to 40% MeCN in water (0.5% TFA)). tert-butyl (3R, 5R)-1-(2-(6-cyanopyridazin-3-yloxy)-4-(4-fluorophenyl)cyclopentyl)-5-fluoropiperidin-3-ylcarbamate (20.00 g, 61,1 %) was obtained as a white solid. The product was further purified by Waters SFC 350 Preparative System [(Column: Lux 5 $\mu\text{m}$  Cellulose-4, 5\*25cm, 5 $\mu\text{m}$ ; Mobile Phase A:  $\text{CO}_2$ : 60%, Mobile Phase B: MeOH: 40%; Flow rate: 150 mL/min; 230 nm; RT1:6.52; RT2:7.27]] to afford isomer 1: (7.00 g, 96.8% ee) and isomer2: (10.00 g, 95.5% ee) as white solids. LCMS: m/z (ESI),  $[\text{M}+\text{H}]^+ = 500$ .

*Step 2. 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyridazine-3-carbonitrile*

#### **Compound 24**



5

Dimethylsulfane (30 mL, 391.94 mmol) and TFA (30 mL, 392.03 mmol) were added dropwise at batches to isomer 2 obtained in the preceding experiment (10 g, 20.02 mmol) in DCM (100 mL) at 25°C. The resulting mixture was stirred at 25 °C for 2h and then the solvent was removed under reduced pressure. C18-flash chromatography (10 to 30% MeCN in water (0.05% TFA)) afforded

10 **Compound 24** (9.00 g, 82 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 400; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.03 (d, 1H), 7.46 - 7.23 (m, 3H), 7.14 - 6.97 (m, 2H), 5.87 (d, 1H), 5.07 (s, 1H), 3.65 (s, 2H), 3.51 - 3.36 (m, 1H), 3.31 (d, 2H), 3.08 - 2.83 (m, 1H), 2.73 (d, 1H), 2.50 (s, 1H), 2.29 (tt, 3H), 1.93 (dq, 2H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ -77.3, -118.76, -185.06.

#### Compound 25

15 *Step 1. tert-butyl (3R)- 1-(2- (5-chloropyridazin-3-yloxy)- 4-(4-fluorophenyl) cyclopentyl) piperidin-3-yl carbamate*

DTAD (487 mg, 2.11 mmol) was added to 5-chloropyridazin-3(2H)-one (207 mg, 1.59 mmol), **F2a** (400 mg, 1,06 mmol) and PPh<sub>3</sub> (554 mg, 2.11 mmol) in DCM (20 mL). The resulting mixture was stirred at 30 °C for 2 hours and then the solvent was removed under reduced pressure. C18 flash column chromatography (40 to 42% MeCN in water (modified with 0.1% aq. NH<sub>3</sub>)) gave the desired product (450 mg, 87 %) as a yellow solid. LCMS : m/z (ESI), [M+H]<sup>+</sup> = 492; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.20 - 1.32 (m, 1H), 1.44 (d, 10H), 1.49 (d, 1H), 1.62 - 1.94 (m, 4H), 1.95 - 2.17 (m, 3H), 2.16 - 2.46 (m, 2H), 2.68 - 2.98 (m, 2H), 3.55 (dt, 3H), 5.64 (tt, 1H), 6.97 - 7.15 (m, 3H), 7.26 - 7.37 (m, 2H), 8.12 (t, 1H).


25 *Step 2. tert-butyl (3R)- 1-(4-(4-fluorophenyl)- 2-(5-fluoropyridazin-3-yloxy) cyclopentyl) piperidin-3-yl carbamate*

KF (237 mg, 4.07 mmol) was added to the foregoing piperidin-3-ylcarbamate compound (400 mg, 0.81 mmol) in DMSO (10 mL). The resulting mixture was stirred at 100 °C for 72h then diluted with DCM (20 mL), and washed with water (25 mL x 3). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to afford crude product. Preparative HPLC [XBridge Prep OBD C18 Column 19\*250mm, 5μm; Mobile Phase A: Water(0.05% aq. NH<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient:

30

5 66% B to 66% B in 8 min; 220,254 nm; Rt: 6.57-7.18 mins] gave tert-butyl (3R)-1-(4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yloxy)cyclopentyl)piperidin-3-ylcarbamate (60.0 mg, 15.52 %) as a yellow solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 475.

*Step 3. 1-[4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yl)oxy-cyclopentyl]piperidin-3-amine* **Compound 25**



10

TFA (3 mL, 0.13 mmol) was added to the carbamate obtained above (60 mg, 0.13 mmol) in DCM (15 mL). The resulting solution was stirred at 25 °C for 2 hours and the solvent was removed under reduced pressure. Preparative HPLC [Column XSelect CSH Prep C18 OBD Column, 5µm, 19\*150mm; Mobile Phase A: Water (0.05% TFA ), Mobile Phase B: MeCN; Flow rate: 25 mL/min; Gradient: 15% B to 25% B in 7 min; 254;220 nm; Rt: 4.42 min] gave **compound 25**, (R)-1-((1S,2S,4R)-4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yloxy)cyclopentyl)piperidin-3-amine, (20.00 mg, 42.2 %) as a colourless oil. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 375; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.23 (d, 1H), 7.30-7.34 (m, 2H), 7.01-7.07 (m, 2H), 6.77 (d, 1H), 5.86 (s, 1H), 4.11 (s, 1H), 3.08-3.58 (m, 4H), 2.89-2.91 (m, 2H), 2.59 (s, 1H), 2.32-2.36 (m, 1H), 2.17-2.27 (m, 1H), 1.85-2.03 (m, 3H), 1.79-1.82 (m, 1H), 1.63-1.66 (m, 1H). <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD) δ -77.16, -111.97.

20

**Compound 26**

*Step 1. tert-butyl (3R)-1-(2-(5-cyanopyridin-2-yloxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate*

To a mixture of **F2a** (360 mg, 0.95 mmol), 6-hydroxynicotinonitrile (114 mg, 0.95 mmol), PPh<sub>3</sub> (499 mg, 1.90 mmol) in THF (25 mL), was added DTAD (438 mg, 1.90 mmol). After stirring for 16 h the solvent was evaporated. The residue was purified by preparative TLC (EtOAc: petroleum ether = 1: 2), to afford tert-butyl the product (280 mg, 61.3 %) as a yellow oil. Prep-HPLC to afforded fraction 1 (120 mg, 33.8 %) as a white solid and fraction 2 (70.0 mg, 19.69 %) as a white solid.


25

Fraction 1: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.67 - 8.76, 8.13 (1 H, s), 7.61 - 7.71 (1 H, m), 7.28 - 7.40 (2 H, m), 7.12 (2 H, t), 6.61 (1 H, s), 6.48 (1 H, dd), 5.33 (1 H, s), 3.54 (2 H, d), 3.26 (2 H, s), 2.77 (1 H, s), 2.15 (4 H, s), 1.61 (7 H, s), 1.35 (9 H, s), 1.20 (1 H, m). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 481.

30

- 5 Fraction 2: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.33 (9 H, d), 1.75 (4 H, s), 2.13 (3 H, s), 5.69 (1 H, s), 6.99 - 7.19 (3 H, m), 7.29 - 7.40 (2 H, m), 8.17 (2 H, d), 8.72 (1 H, s); LCMS: m/z (ESI), [M+H]<sup>+</sup> = 481.

Step 2. 6-(2-((R)-3-aminopiperidin-1-yl)-4-(4-fluorophenyl)cyclopentyloxy)nicotinonitrile **Compound 26**



- To a solution of the above fraction 2 (70 mg, 0.15 mmol) in DCM (15 mL), was added TFA (0.15 mL, 1.95 mmol). The reaction mixture was stirred at 25 °C for 1 hour and concentrated to dryness. The residue was purified by preparative HPLC, [water (containing 0.05% NH<sub>3</sub>) and MeCN gradient] to give a white solid (50.0 mg, 90 %), which was further purified by prep-chiral-HPLC to afford 6-(2-((R)-3-aminopiperidin-1-yl)-4-(4-fluorophenyl)cyclopentyloxy)nicotinonitrile isomer 1, **Compound 26** (22.70 mg, 32.4 %) as a white solid and isomer 2 (15.50 mg, 22.14 %). **Compound 26** showed: <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.24 (1 H, t), 1.49 - 1.81 (3 H, m), 1.89 (1 H, dq), 2.02 - 2.29 (4 H, m), 2.34 - 2.49 (1 H, m), 2.79 - 2.93 (2 H, m), 3.01 (1 H, d), 3.11 - 3.41 (2 H, m), 5.60 (1 H, ddd), 6.88 - 7.09 (3 H, m), 7.22 - 7.36 (2 H, m), 7.98 (1 H, dd), 8.56 (1 H, dd). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 381.


- Isomer 2: <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>) δ 1.17 (1 H, td), 1.53 - 2.28 (9 H, m), 2.32 - 2.47 (1 H, m), 2.78 - 2.93 (2 H, m), 3.01 (1 H, d), 3.09 - 3.39 (1 H, m), 5.58 (1 H, d), 6.89 - 7.07 (3 H, m), 7.28 (2 H, dd), 7.97 (1 H, dt), 8.55 (1 H, d). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 381.

### Compound 27

Step 1. *tert*-butyl (3R)-1-(2-(6-cyanopyridin-3-yloxy)-4-(4-fluorophenyl) cyclopentyl) piperidin-3-yl carbamate

- F2a** (226.8 mg, 0.60 mmol), 5-hydroxypicolinonitrile (86 mg, 0.72 mmol) and Ph<sub>3</sub>P (393 mg, 1.50 mmol) in DCM (10 mL) were reacted at 0°C with DTAD (276 mg, 1.20 mmol). The reaction was allowed to warm to rt over 2h. After standard work up C18 flash column chromatography, (0 to 45% MeCN in water (0.1M aq. NH<sub>3</sub>)) gave *tert*-butyl (3R)-1-(2-(6-cyanopyridin-3-yloxy)-4-(4-fluorophenyl)cyclopentyl) piperidin-3-yl carbamate (160 mg, 55.6 %) as a light red solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 481.30. Preparative chiral-HPLC [(Column: Chiralpak IA, 2\*25cm, 5μm; Mobile Phase: Phase A: Hexanes-HPLC Phase B: EtOH-HPLC Gradient; Flow rate: 20 mL/min; Gradient: A:B = 90:10 in 12.5min; 254/220 nm; RT1:11.13; RT2:14.44)] afforded two fractions containing isomer 1 (30 mg, 0.06 mmol) and isomer 2 (30 mg, 0.06 mmol) as white solids.

5 *Step 2. 6-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyridine-3-carbonitrile Compound 27*




To a stirred solution of isomer 1 (30 mg, 0.06 mmol) in DCM (2 mL) was added TFA (0,66 mL) at r.t for 16h. Purification by preparative HPLC (XBridge Prep C18 OBD column, 5 $\mu$  silica, 19 mm diameter, 10 150 mm length, water (containing 0.05% TFA)/MeCN gradient) gave **Compound 27**, (24.00 mg, 90 %) as a white solid which proved to be the most potent isomer. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 381; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.43 (s, 1H), 8.33 (s, 1H), 7.85 (d, 1H), 7.56 (d, 1H), 7.32 (dd, 2H), 7.16 - 6.97 (m, 2H), 4.92 (s, 2H), 3.38 (s, 2H), 2.93 (d, 1H), 2.61 (d, 3H), 2.38 (dt, 1H), 2.21 (t, 2H), 2.05 - 1.76 (m, 3H), 1.77 - 1.48 (m, 2H).

15 **Compound 28**

*Step 1. tert-butyl 1-((1R)-4-(4-fluorophenyl)-2-(pyridazin-3-yloxy)cyclopentyl)piperidin-3-yl carbamate* DIAD (427 mg, 2,11 mmol) PPh<sub>3</sub> (554 mg, 2,11 mmol), pyridazin-3(2H)-one (152 mg, 1,59 mmol) and **F2a** (400 mg, 1,06 mmol) in DCM (10 mL) were reacted under standard Mitsunobu conditions. After 2h at rt the solvent was removed under reduced pressure. C18 flash column chromatography, (45 to 20 50% MeCN in water (modified with 0.1 aq. NH<sub>3</sub>) gave tert-butyl ((3R)-1-(4-(4-fluorophenyl)-2-(pyridazin-3-yloxy)cyclopentyl)piperidin-3-yl)carbamate (400 mg, 83 %) as a yellow solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 457; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  1.17 - 1.33 (m, 1H), 1.45 (d, 9H), 1.51 - 2.14 (m, 4H), 2.18 - 2.50 (m, 2H), 2.66 - 2.90 (m, 1H), 2.94 (d, 1H), 3.38 (s, 2H), 3.49 - 3.66 (m, 3H), 5.64 - 5.79 (m, 1H), 6.93 - 7.12 (m, 3H), 7.26 - 7.49 (m, 3H), 8.09 (ddd, 1H). Preparative chiral-HPLC [Chiralpak IB, 25 eluting isocratically with 40% IPA in Hexanes (modified with 0.1% DEA) as eluent] afforded tert-butyl 1-((1R)-4-(4-fluorophenyl)-2-(pyridazin-3-yloxy)cyclopentyl)piperidin-3-ylcarbamate isomer 1 (180 mg, 45.0%, 99.5% ee) as a yellow solid and isomer 2 (180 mg, 45.0 %, 99.5% ee) as a yellow solid. LCMS (for both isomers) m/z (ESI), [M+H]<sup>+</sup> = 457.

*Step 2. 1-[4-(4-fluorophenyl)-2-pyridazin-3-yloxy-cyclopentyl]piperidin-3-amine Compound 28*



5

TFA (2 mL, 25.96 mmol) was added to isomer 1 obtained above (180 mg, 0.39 mmol) in DCM (10 mL). The resulting mixture was stirred at 25 °C for 2 hours. The solvent was then removed under reduced pressure and the crude product was purified by preparative HPLC [X select CSH OBD Column 30\*150mm 5µm; Mobile Phase A: Water (0.05% TFA), Mobile Phase B: MeCN; Flow rate: 60 mL/min; Gradient: 11% B to 21% B in 7 min; 254; 220 nm; Rt: 5.57 min] to afford **Compound 28** (240 mg, 70.7 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 357; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.56 - 1.75 (m, 1H), 1.82 - 2.31 (m, 5H), 2.47 (ddd, 1H), 2.65 - 2.80 (m, 1H), 2.93 (t, 1H), 3.08 (t, 1H), 3.66 (dtd, 4H), 4.32 (dt, 1H), 5.99 (ddd, 1H), 6.99 - 7.14 (m, 3H), 7.29 - 7.42 (m, 2H), 7.48 (dd, 1H), 8.14 (dd, 1H). <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD) δ -77.173 (m, 13F), -118.211 (s, 1F).


### 15 **Compound 29**

*Step 1. tert-butyl (3R,5R)-5-fluoro-1-(4-(4-fluorophenyl)-2-(pyrimidin-4-yloxy)cyclopentyl)piperidin-3-ylcarbamate*

DTAD (581 mg, 2.52 mmol) was added to **F2b** (500 mg, 1.26 mmol), pyrimidin-4-ol (145 mg, 1.51 mmol) and PPh<sub>3</sub> (827 mg, 3.15 mmol) in DCM (15 mL) at 0°C over a period of 5 minutes. The resulting solution was stirred at 25 °C for 2 hours. The solvent was removed under reduced pressure. C18 flash column chromatography (40 to 50% water in MeCN) gave fraction 1 (former peak : 200 mg, 33.4 %) as a colourless oil and fraction 2 (later peak : 300 mg, 50.1%) as a white solid. Fraction 2 was further separated and purified by preparative chiral-HPLC on a CHIRALPAK IA-3 column, eluting isocratically with 50% IPA in petroleum ether (modified with diethylamine) as eluent. The fractions containing the desired compound were evaporated to dryness to afford isomer 1 tert-butyl((3S,5R)-5-fluoro-1-((1S,2S,4R)-4-(4-fluorophenyl)-2-(pyrimidin-4-yloxy)cyclopentyl)piperidin-3-yl)carbamate (160 mg, 41%, 100% ee) as a white solid and isomer 2 (110 mg, 28.2%, 99.6% ee) as a white solid. LCMS for both isomers: m/z (ESI), [M+H]<sup>+</sup> = 475.

*Step 2. 5-fluoro-1-[4-(4-fluorophenyl)-2-pyrimidin-4-yloxy-cyclopentyl]piperidin-3-amine **Compound 29***

30



5

TFA (3 mL, 0.34 mmol) was added to above isomer 1 (160 mg, 0.34 mmol) in DCM (15 mL). The resulting solution was stirred at 25 °C for 2 hours. Preparative HPLC [XBridge Prep OBD C18 Column 30×150mm 5µm; Mobile Phase A:Water (0.05% aq. NH<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 60 mL/min; Gradient: 28% B to 40% B in 7 min; 254/220 nm; Rt: 5.95 min] gave **Compound 29** as a white solid (75.0 mg, 59.0 %). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 375; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.75 (dd, 1H), 8.46 (dd, 1H), 7.38 - 7.24 (m, 2H), 7.09 - 6.89 (m, 3H), 5.62 (ddd, 1H), 4.90 (d, 0.5H), 4.76 (s, 0.5H), 3.35 (s, 1H), 3.30 - 3.01 (m, 4H), 2.51 - 1.96 (m, 6H), 1.77 (td, 1H), 1.44 (dt, 1H). <sup>19</sup>F NMR (300 MHz, CD<sub>3</sub>OD) δ -183.07, -119.12

10

### Compound 30

15 *Step 1. tert-butyl (3R)-1-(2-(5-bromopyrimidin-2-yloxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl carbamate*

To a solution of **F2a** (900 mg, 2.38 mmol) in DMF (6 mL) was added NaH (190 mg, 4.76 mmol) at rt. The mixture was stirred for 3 min, then 5-bromo-2-chloropyrimidine (690 mg, 3.57 mmol). After 8h the reaction mixture was quenched with saturated NH<sub>4</sub>Cl (aq). (30 mL) and extracted with DCM (2 x 20 mL), the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to afford crude product. Preparative TLC (EtOAc:petroleum ether = 1:2), gave the product (500 mg, 39.3 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 379.

20

*Step 2. tert-butyl (3R)-1-(2-(5-cyanopyrimidin-2-yloxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-yl carbamate*


25 To a solution of the above carbamate (330 mg, 0.62 mmol) in DMF (5 mL) was added Zn(CN)<sub>2</sub> (145 mg, 1.23 mmol) and zinc (4.03 mg, 0.06 mmol) at rt. Pd<sub>2</sub>dba<sub>3</sub> (106.8 mg, 0.12 mmol) and dppf (137 mg, 0.25 mmol) were then added and the reaction stirred for 3h at 120 °C. After dilution with EtOAc (20 mL), and washing (water (10 mL x 2), saturated brine (10 mL)), the combined organics were dried over and evaporated. The residue was purified by preparative TLC (DCM: MeOH = 50: 1), to afford a crude product (200 mg, 67.4 %) as a yellow solid. Preparative chiral-HPLC (Column: CHIRAL Cellulose-SB size: 0.46\*15cm; 3µm. Mobile phase: Hexanes (0.1% DEA): IPA=80:20; Flow rate: 1.0 mL/min; Detector:

30

- 5 UV-254nm; RT1:7.353; RT2:8.710) afforded tert-butyl (R)-1-((1S,2S,4R)-2-(5-cyanopyrimidin-2-yloxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate isomer 1 (120 mg, 57.1 %, 100% ee), and isomer 2 (50.0 mg, 23.81 %, 98.7% ee) as white solids. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 482.

Step 3. 2-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrimidine-5-carbonitrile

### Compound 30



10


- To a solution of the above isomer 1 (120 mg, 0.25 mmol) in DCM (2 mL) was added TFA (0.66 mL) at rt. After stirring for 16h and standard work up the crude product was purified by preparative HPLC (Column: XSelect CSH Prep C18 OBD Column, 5 $\mu$ m, 19\*150mm; Mobile Phase A: Waters (0.1% FA), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 2% B to 27% B in 7 min; 220,254 nm) to afford
- 15 **Compound 30** (100 mg, 93 %), as a white solid, which proved to be the potent isomer. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$  8.98 (s, 2H), 8.31 (s, 1H), 7.32 (d, 2H), 7.04 (t, 2H), 5.59 (d, 1H), 3.42 (br s, 1H), 3.26 (s, 1H), 2.96 (d, 1H), 2.85 - 2.67 (m, 1H), 2.67 - 2.51 (m, 2H), 2.43 (d, 1H), 2.23 (d, 2H), 2.05 - 1.46 (m, 5H). LCMS: m/z (ESI), [M+H]<sup>+</sup> = 382.

### Compound 31

- 20 *Step 1. tert-butyl (3R)-1-(2-(5-bromopyrimidin-2-yloxy)-4-(4-fluorophenyl)cyclopentyl) piperidin-3-yl carbamate*

- To a solution of **F2a** (900 mg, 2.38 mmol) in DMF (6 mL) was added NaH (190 mg, 4.76 mmol) at rt. The mixture was stirred for 3 min then 5-bromo-2-chloropyrimidine (690 mg, 3.57 mmol) was introduced. The reaction was worked up after 8h stirring. Purification by Prep-TLC to give the product
- 25 (500 mg, 39.3 %) as a white solid. This crude product was further purified by preparative chiral-HPLC [(CHIRALPAK IC-3 size: 0.46\*10cm; 3 $\mu$ m. Mobile phase: Hexanes (0.1%DEA): EtOH=80:20; Flow rate: 1 mL/min; Detector:254nm; RT1:4.759; RT2:5.595) to afford tert-butyl (3R)-1-(2-(5-cyanopyrazin-2-yloxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate isomer 1 (100 mg, 55.6 %, 99.9% ee), and isomer 2 (50.0 mg, 27.8 %, 100% ee) as white solid.

- 30 *Step 2. 5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrazine-2-carbonitrile* **Compound 31**



5

To a solution of isomer 2 obtained above (50 mg, 0.10 mmol) in DCM (2 mL) was added TFA (0.5 mL, 6.5 mmol) at rt. The reaction was stirred for 2h then subjected to standard work up. The crude product was purified by preparative HPLC [XBridge Prep C18 OBD Column, 5 $\mu$ m, 19\*150mm; Mobile Phase A: Waters (10 mmol/L NH<sub>4</sub>HCO<sub>3</sub>), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 20% B to 33% B in 20 min; 254/220 nm to give **Compound 31** (30.0 mg, 76 %) as a white solid LCMS: m/z (ESI), [M+H]<sup>+</sup> = 382.4; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  8.64 (s, 1H), 8.36 (s, 1H), 7.30 (dd, 2H), 7.04 (t, 2H), 5.65 - 5.53 (m, 1H), 3.51 - 3.35 (m, 3H), 2.93 (d, 1H), 2.71 (d, 1H), 2.57 (d, 2H), 2.42 (s, 1H), 2.20 (dd, 2H), 2.02 - 1.89 (m, 1H), 1.89 - 1.72 (m, 2H), 1.65 (d, 2H).


### Compound 32

15 *Step 1. tert-butyl (3R)-1-(2-(2-cyanopyrimidin-5-yloxy)-4-(4-fluorophenyl) cyclopentyl) piperidin-3-yl carbamate*

To a solution of **F2a** (260 mg, 0.69 mmol), 5-hydroxypyrimidine-2-carbonitrile (100 mg, 0.82 mmol) and Ph<sub>3</sub>P (270 mg, 1.03 mmol) in DCM (10 mL) at 0 °C, was added DTAD (237 mg, 1.03 mmol). The mixture was stirred for 2h at 25 °C. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> (100 mL), extracted with DCM (2 x 50 mL), then dried and evaporated to afford an orange gum. Preparative HPLC (XBridge Prep C18 OBD column, 5 $\mu$ m silica, 19 mm diameter, 150 mm length, water (containing 0.05% NH<sub>3</sub>)/MeCN gradient) gave the product (190 mg, 57.4 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 482. Preparative chiral-HPLC [Column: CHIRALPAK IC, 2.0cm I.D\*25cm L; Mobile Phase A:Hexanes-HPLC, Mobile Phase B: EtOH-HPLC; Flow rate: 20 mL/min; Gradient: A:B = 85:15 in 24 min; 20 gave tert-butyl (3R)-1-(2-(2-cyanopyrimidin-5-yloxy)-4-(4-fluorophenyl)cyclopentyl)piperidin-3-ylcarbamate isomer 1 (first fraction ; 95 mg, 50.0 %, 100% ee) and isomer 2 (second fraction ; 100 mg, 52.6 %, 88.6% ee).

25 *Step 2. 5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrimidine-2-carbonitrile*

### Compound 32



5

To a solution of the isomer 2 (100 mg, 0.21 mmol) obtained above in DCM (10 mL) was added TFA (0.66 mL) at 25 °C. The reaction mixture was stirred for 16h then worked up. The crude product was purified by preparative HPLC (Column: XSelect CSH Prep C18 OBD Column, 5 μm, 19 mm x 150 mm; Mobile Phase A: Waters (0.05% TFA), Mobile Phase B: MeCN; Flow rate: 20 mL/min; Gradient: 10% B to 32% B in 7 min; 254; 220 nm) to give **Compound 32** (80 mg, 51.6 %) as a white solid. LCMS: m/z (ESI), [M+H]<sup>+</sup> = 382; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.63 (s, 2H), 7.42 - 7.26 (m, 2H), 7.13 - 6.97 (m, 2H), 5.57 - 5.40 (m, 1H), 4.08 (ddd, 1H), 3.76 - 3.36 (m, 5H), 3.11 (q, 2H), 2.63 (ddd, 1H), 2.35 (dtd, 2H), 2.23 - 2.01 (m, 3H), 2.01 - 1.81 (m, 1H), 1.70 (dd, 1H). <sup>19</sup>F NMR (282 MHz, CD<sub>3</sub>OD) δ -77.14, -118.01.

10

#### X-Ray crystallographic studies of Compound 10, Form A.

The sample of compound 10 obtained as described above was mounted on single silicon crystal (SSC) wafer mount and powder X-ray diffraction was recorded with a Theta-Theta PANalytical X'Pert PRO (wavelength of X-rays 1.5418 Å nickel-filtered Cu radiation, Voltage 45kV, filament emission 40 mA). Automatic variable divergence and anti-scatter slits were used and the samples were rotated during measurement. Samples were scanned from 2 - 50° 2Theta using a 0.013° step width and a 233 seconds step measurement time using a PIXCEL detector (active length 3.35° 2Theta).

20

The 13 most prominent X-Ray powder diffraction peaks for Compound 10, Form A, are reported in Table 1 above. relative intensity values of Table 1 are assigned according to the definitions of Table 3 below.

**Table 3**

% Relative Intensity*	Definition
25 - 100	vs (very strong)
10 - 25	s (strong)
3 - 10	m (medium)

5

\* The relative intensities are derived from diffractograms measured with fixed slits


.0

Where any or all of the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components.

A reference herein to a patent document or any other matter identified as prior art, is not to be taken as an admission that the document or other matter was known or that the information it contains was part of the common general knowledge as at the priority date of any of the claims.

5 The claims defining the invention are as follows:

1) A compound of Formula I



Formula I

wherein:

- .0 X is a) O, and R<sup>1</sup> is a 6-membered aromatic or heteroaromatic ring selected from phenyl, pyridyl, pyrimidyl, pyrazinyl or pyridazyl, wherein R<sup>1</sup> is optionally substituted with one or two substituents Y independently selected from F, Cl, Br, CN, OH, OC<sub>1-3</sub>alkyl, OCF<sub>3</sub>, C<sub>1-3</sub>alkyl, C(O)NH<sub>2</sub>, CF<sub>3</sub> or cyclopropyl; or b) NR<sup>2</sup>, and wherein N, R<sup>1</sup> and R<sup>2</sup> together form a 5-membered aromatic heterocycle that is optionally substituted with one or two substituents Y that are independently selected from F, Cl, CN,
- .5 or Me;
- R<sup>3</sup> is independently selected from F, Cl, CN, methyl, methoxy, hydroxy and ethynyl;
- R<sup>4</sup> is independently selected from F or Cl attached to C2, C4 or C5 of the piperidine ring; and the integers a and b are independently selected from 0, 1 or 2;
- or a pharmaceutically acceptable salt thereof.
- 20 2) The compound according to claim 1 wherein the piperidine group and the group XR<sup>1</sup> are in the *trans*-configuration.
- 3) The compound according to claim 1 or claim 2 wherein the piperidine and the phenyl group are in the *cis*-configuration.
- 4) The compound according to any one of claims 1 to 3 wherein a substituent R<sup>3</sup> is located
- 25 *para*-to the bond to the cyclopentane ring.
- 5) The compound according to claim 4 wherein the substituent R<sup>3</sup> is F and a = 1.
- 6) The compound according to any one of claims 1 to 5, wherein X is O.

- 5 7) The compound according to claim 6, wherein the 6-membered aromatic or heteroaromatic ring R<sup>1</sup> is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl or pyridazyl and wherein R<sup>1</sup> is substituted with at least one substituent Y selected from Me, Cl, F and CN.
- 8) The compound according to any one of claims 1 to 5, wherein X is NR<sup>2</sup>.
- 9) The compound according to claim 8, wherein the 5-membered aromatic heterocycle comprising NR<sup>1</sup>R<sup>2</sup> is unsubstituted.
- 10) The compound according to claim 8 or claim 9, wherein the 5-membered aromatic heterocycle comprising NR<sup>1</sup>R<sup>2</sup> is selected from pyrrole, imidazole, pyrazole and 1,2,4-triazole.
- 11) The compound according to claim 1 selected from:
- 1-[4-(4-fluorophenyl)-2-(triazol-2-yl)cyclopentyl]piperidin-3-amine;
- 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile;
- 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-3-carbonitrile;
- 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrrole-3-carbonitrile;
- 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]triazole-4-carbonitrile;
- 1-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile;
- 10 1-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]pyrazole-4-carbonitrile;
- 1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine;
- 5-fluoro-1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl]piperidin-3-amine;
- 5-fluoro-1-[4-(4-fluorophenyl)-2-(1,2,4-triazol-1-yl)cyclopentyl]piperidin-3-amine;
- 5-fluoro-1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine;
- 15 1-[4-(4-fluorophenyl)-2-(tetrazol-2-yl)cyclopentyl]piperidin-3-amine;
- 1-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentyl]-1,2,4-triazole-3-carbonitrile;
- 4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-hydroxy-phenyl)cyclopentoxyl]benzonitrile;
- 4-[2-(3-amino-1-piperidyl)-4-(4-fluoro-3-methoxy-phenyl)cyclopentoxyl]benzonitrile;
- 4-[2-(3-amino-1-piperidyl)-4-(3-fluorophenyl)cyclopentoxyl]-3-chloro-benzonitrile;
- 30 4-[2-(3-amino-4,4-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]benzonitrile;
- 4-[2-(5-amino-3,3-difluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]benzonitrile;
- 4-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]-2-fluoro-benzonitrile;
- 2-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxyl]benzonitrile;
- 4-[2-(3-amino-1-piperidyl)-4-phenyl-cyclopentoxyl]-3-chloro-benzonitrile;
- 35 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxyl]-5-methyl-pyridazine-3-carbonitrile;
- 1-[2-(4-chloropyridazin-3-yl)oxy-4-(4-fluorophenyl)cyclopentyl]piperidin-3-amine;

5 6-[2-(3-amino-5-fluoro-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyridazine-3-carbonitrile;  
1-[4-(4-fluorophenyl)-2-(5-fluoropyridazin-3-yl)oxy-cyclopentyl]piperidin-3-amine;  
6-(2-((R)-3-aminopiperidin-1-yl)-4-(4-fluorophenyl)cyclopentyloxy)nicotinonitrile;  
6-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyridine-3-carbonitrile;  
1-[4-(4-fluorophenyl)-2-pyridazin-3-yloxy-cyclopentyl]piperidin-3-amine;  
.0 5-fluoro-1-[4-(4-fluorophenyl)-2-pyrimidin-4-yloxy-cyclopentyl]piperidin-3-amine;  
2-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrimidine-5-carbonitrile;  
5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrazine-2-carbonitrile; and  
5-[2-(3-amino-1-piperidyl)-4-(4-fluorophenyl)cyclopentoxy]pyrimidine-2-carbonitrile;  
or a pharmaceutically acceptable salt thereof.

.5 12) (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine, or a pharmaceutically acceptable salt thereof.

13) A crystalline form of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine.

10 14) Crystalline Form A of (3R,5R)-5-fluoro-1-((1R,2R,4S)-4-(4-fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)cyclopentyl)piperidin-3-amine.

15) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 or the crystalline form according to claim 13 or the crystalline form A according to claim 14, and at least one pharmaceutically acceptable diluent, excipient or inert carrier.

15 16) A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 or the crystalline form according to claim 13 or the crystalline form A according to claim for use in the manufacture of a medicament, optionally wherein the medicament is for the treatment of kidney disease.

30 17) A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 or the crystalline form according to claim 13 or the crystalline form A according to claim 14, for use in as a medicament.


35 18) A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 or the crystalline form according to claim 13 or the crystalline form A according to claim 14, for use in the treatment or prophylaxis of diseases and conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial.

5 19) A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 or the crystalline form according to claim 13 or the crystalline form A according to claim 14, for use in the treatment of kidney disease, optionally wherein the disease is focal segmental glomerulosclerosis (FSGS) with a TRPC6 gain of function mutation.

.0 20) Method of treatment comprising administration of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 or the crystalline form according to claim 13 or the crystalline form A according to claim 14, to a patient in need thereof, wherein the patient has diseases and conditions in which inhibition of TRPC6 and/or TRPC3 is beneficial.

.5 21) The method of treatment according to claim 20 wherein the patient in need has kidney disease, optionally wherein the disease is focal segmental glomerular sclerosis with a TRPC6 gain of function mutation.

22) Process for the preparation of a compound of Formula I involving the step



wherein P is a protecting group and the remaining groups are as defined in claim 1.

**Figure 1: X-Ray Powder Diffraction Pattern Compound 10, Form A**

(y-axis = relative intensity)

